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ABSTRACT 
Metal-organic framework (MOF) is a type of emerging porous material that 
demonstrates promising potentials in energy, sensing, conversion, separation, and more 
recently, enzyme encapsulation. However, the research of enzyme-MOF composites 
mainly focuses on the synthetic strategy, and practical applications of enzyme-MOF 
composites have yet been mentioned in the literature. In this dissertation, the performance 
of enzyme-MOF composites in biomedical applications will be discussed in detail. 
The chemical stability of MOFs in aqueous solutions is a prerequisite for enzyme 
immobilization. Bearing this in mind, a novel reductive labilization strategy for the 
preparation of an ultrastable Cr(III)-MOF from Fe(III)-MOF is discovered, which might 
be useful for the improvement of material stability in aqueous media. The resulting 
Cr(III)-MOF shows much broader pH tolerance in aqueous solutions and can be used to 
incorporate polyethylenimine (PEI) for carbon dioxide capture. 
Most of the current enzyme-MOF composites only carry single enzymatic 
function, while multi-enzyme immobilized materials may be superior in complex 
systems. To achieve this goal, a novel mesoporous MOF, PCN-888, is rationally designed 
to accommodate two enzymes, glucose oxidase (GOx) and horseradish peroxidase (HRP), 
via a stepwise encapsulation manner. This bienzymatic MOF nanoreactor persists 
enzymatic activities very well and is resistant to trypsin digestion. 
Based on the above-mentioned stepwise encapsulation strategy, a nanoscale 
bienzymatic nanofactory is prepared based on PCN-333. This nanofactory can be 
endocytosed by living cells, accumulated in lysosomes, and exert protective effect to cells 
against oxidative damage. More importantly, because of the preservation of enzyme 
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structure and function by the MOF material, the enzymatic activity of enzyme-MOF 
nanofactory can last as long as one week after the nanofactory is internalized. 
Inspired by the long-lasting performances of enzyme-PCN-333 nanofactory, a 
therapeutic enzyme-PCN-333 nanoreactor is developed to activate a nontoxic prodrug in 
cancer cells. In this case, tyrosinase (TYR) is encapsulated and can convert innocent 
paracetamol to cytotoxic o-quinone species in cancer cells. This prodrug activation 
process can effectively kill multiple types of cancer cells, including a drug resistant cell 
line. The effectiveness of this strategy is further proved on in vivo models bearing human 
tumor xenograft. 
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CHAPTER I 
INTRODUCTION TO METAL-ORGANIC FRAMEWORKS AND ENZYME 
IMMOBILIZATION1 
1.1 Introduction to metal-organic frameworks 
Metal-organic framework (MOF) is a type of coordination material that is 
composed of metal containing clusters and organic ligands. The key chemical feature of 
MOF is coordination bond.1 In most MOF materials, the metal ion adopts a coordination 
environment that is very similar to that of small molecular mononuclear or multinuclear 
coordination compounds. The organic ligand connects the individual coordination clusters 
and results in long-range order of unit cells.  
Porosity is one of the most intriguing features of MOF materials. Compared with 
other porous materials, such as activated carbon, silica materials, zeolites, and polymer 
materials, MOFs possess unprecedented surface area and porosity.2 This is attributed to 
the crystalline nature of MOF materials, whereas most of the other materials are 
amorphous and do not possess intrinsic porosity. The size of MOF cavity can also be 
tuned into microporous (<2 nm), mesoporous (2-50 nm), and macroporous (>50 nm).3 
The tunability of MOF pore size renders that substrates with different sizes, ranging from 
gas molecules (N2, O2, CO2, CH4, etc.) to macromolecules (proteins, coordination cages, 
heteropolyacids, etc.), can be adsorbed, encapsulated, or diffused through the MOF 
cavities, which indicates that MOFs have application potentials in energy, catalysis, 
sensing, or biomedical aspects.4-68 
1 Part of this chapter is reproduced with permission from “Enzyme-MOF (metal-organic framework) Composite” by 
Lian, X.; Fang, Y.; Joseph, E.; Wang, Q.; Li, J.; Banerjee, S.; Lollar, C.; Wang, X.; Zhou, H.-C. Chem. Soc. Rev., 2017, 
46, 3386-3401, copyright 2017 by Royal Society of Chemistry. 
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1.2 Synthetic approaches of stable MOFs 
The stability of MOFs in aqueous conditions is a prerequisite for MOF 
applications in biomedical researches. Given that carboxylate ligand is the most 
extensively used ligand for MOF synthesis, the preparation procedures of stable 
carboxylate-based MOF materials will be introduced. Based on the Hard and Soft Acid 
and Base (HSAB) theory, since oxygen is hard Lewis base, hard Lewis acid species 
should be employed in the preparation of stable MOFs.69 Therefore, high valent metal 
species, such as Zr(IV), Hf(IV), Fe(III), Al(III), Cr(III), are the most extensively studied 
metal sources because they tend to form stronger coordination bonds with carboxylate 
ligands than mono- or di-valent metal species.16  
The key factor to gain crystalline MOFs other than amorphous products in 
solvothermal reactions is to control the equilibrium of the formation and dissociation of 
the coordination bond between metal ions and ligands. The formation of coordination 
bonds between M(III)/M(IV) with oxygen is thermodynamically favourable, however, the 
dissociation is typically not, even under elevated temperatures. This imbalance can result 
in the formation of undesirable amorphous products. To establish the formation-
dissociation equilibrium between high valent metal species and ligands, modulating 
reagents are generally utilized in the stable MOF synthesis, including non-coordinating 
acid (e.g. HCl, HNO3, HBF4, etc.) to slow down the deprotonation of the carboxylic acid, 
or coordinating acid (e.g. acetic acid, trifluoracetic acid, benzoic acid, etc.) to slow down 
the bond formation between metal species and the ligands.16, 70-77 Herein some well-
known stable MOFs constructed with high valent metal species and carboxylate ligands 
will be introduced in detail. 
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UiO-66, developed by in 2008, consists of 12-connected Zr6O4(OH)4 metal cluster 
and benzenedicarboxylic acid (BDC) ligand (Figure I-1).73 In the structure, the metal 
clusters are expanded versions of cubic close packed (CPP) structure. The inner cavity of 
UiO-66 can be accessed through the triangular window openings. UiO-66 demonstrates a 
Langmuir surface area of 1187 m2/g. It shows chemical stability in a number of solvents 
(water, DMF, benzene, and acetone) and thermal stability up to 540oC, which is among 
the highest values for all MOF materials. Replacing the BDC ligand with BPDC or TPDC 
ligand generates UiO-67 and UiO-68 structures, respectively, with increased surface area 
of the materials (3000 and 4170 m2/g for UiO-67 and -68, respectively), whereas the 
chemical stability of the material does not compromise with the increase of ligand length. 
UiO MOFs with decorated functionalities are also achievable through one-pot synthesis 
or post-synthetic modifications. 
 
Figure I-1. Structure of UiO-66~68. (a) One unit cell of copper drawn to scale with: (b) 
Zr MOF with 1,4-benzene-dicarboxylate (BDC) as linker, UiO-66, (c) Zr MOF with 4,4′ 
biphenyl-dicarboxylate (BPDC) as linker, UiO-67, (d) Zr MOF with terphenyl dicarboxylate 
(TPDC) as linker, UiO-68. Zirconium, oxygen, carbon, and hydrogen atoms are red, blue, 
gray, and white, respectively. Reprinted with permission from Ref. 73, copyright © 2008 
American Chemical Society. 
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A series of Zr-porphyrinic MOFs with exceptional stability are reported by Zhou et 
al, with the name of PCN-22X (X = 1~5).74-78 All PCN-22X MOFs are composed of 
TCPP ligand. PCN-221 is composed of Zr8/Hf8 cluster, which is unprecedented in 
molecular chemistry (Figure I-2).76 The Zr8/Hf8 cluster is connected by 12 carboxylate 
groups with Oh symmetry. Therefore, such a connectivity leads to a very rare (4,12)-
connected ftw topology. Metalloporphyrinic ligand can also be incorporated in PCN-221 
and Zr-PCN-221(Fe) demonstrates very high catalytic activity in the cyclohexane 
oxidation by tert-butyl hydroperoxide (TBHP) at 65oC. Cyclohexanone is the main 
product with an 86.9% yield whereas a small amount of cyclohexanol (5.4%) is produced 
as a side product.  
 
 
 
 
Figure I-2. Optical image of PCN-221(Fe) (left), structure of PCN-221(Fe) (middle), and Zr8 
cluster (right). Reprinted with permission from Ref. 76, copyright © 2013 American 
Chemical Society. 
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PCN-222 is composed of an 8-connected Zr6 cluster and TCPP ligand (free acid 
form and metallated form) (Figure I-3).74 PCN-222 contains one of the largest 1D 
channels with a diameter of up to 3.7 nm. The Brunauer-Emmett-Teller (BET) surface 
area of PCN-222(Fe) after activation is 2200 m2/g. PCN-222(Fe) demonstrates 
exceptional chemical stability relative to all known MOFs. It survives concentrated HCl 
24 h treatment as illustrated by the almost unchanged PXRD pattern and N2 isotherm 
before and after treatment. The high porosity as well as the extraordinary stability of 
PCN-222(Fe) suggests that it can be a biomimetic heterogenous catalysis based on the 
activity of the metalloporphyrin centers. Model reactions (H2O2 oxidation of pyrogallol, 
3,3,5,5, -tetramethylbenzidine, o-phenylenediamine catalysed by PCN-222(Fe)) 
demonstrates that PCN-222(Fe) has superior activities than hemin and can be regarded as 
an example of enzyme-mimic catalyst. 
 
Figure I-3. Crystal structure and underlying network topology of PCN-222(Fe). The Fe-
TCPP (a; blue square) is connected to four 8-connected Zr6 clusters (b; light orange cuboid) 
with a twisted angle to generate a 3D network in Kagome-like topology (d,e) with 1D large 
channels (c; green pillar). Zr black spheres, C gray, O red, N blue, Fe orange. H atoms were 
omitted for clarity. Reprinted with permission from Ref. 74, copyright © 2012 John Wiley 
and Sons. 
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PCN-223 is constructed from a rare 12-connected Zr6 cluster and TCPP (free-base 
or Fe-coordinated) ligand (Figure I-4).78 The 12-connected cluster demonstrates D6h 
symmetry and overall gives rise to the first shp-a topology among all reported MOFs. 
PCN-223 possesses uniform triangular 1D channels of 1.2 nm. Because of the very high 
connection number of Zr6 cluster, PCN-223 exhibits extraordinary stability in aqueous 
solutions with pH value ranging from 0 to 10. Moreover, the high concentration of 
porphyrinic active sites in PCN-223 results in exceptional catalytic activity in hDa 
reaction. 
 
 
Figure I-4. Structure of PCN-223. (a, b) Views of PCN-223 along the c axis (a) with uniform 
triangular 1D channels observed in the structure and (b) after removal of disorder. (c–e) 
Topology analysis of PCN-223. Reprinted with permission from Ref. 78, copyright © 2014 
American Chemical Society. 
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PCN-224 is composed of a 6-connected D3d Zr6 cluster and TCPP (free base, Ni, 
Fe, Co) ligand (Figure I-5).75 Owing to the reduced connection number of metal cluster 
compared with PCN-222 (8-connected) or PCN-223 (12-connected), PCN-224 
demonstrates very high BET surface area (2600 m2/g). On the other hand, the reduced 
connection number does not lead to decrease in chemical stability. PCN-224 is stable in 
aqueous solutions with pH ranging from 0 to 11. Therefore, PCN-224 can be an excellent 
platform for heterogenous catalysis. PCN-224(Co) mediates the production of cyclic 
carbonates from CO2 and epoxides with very high turnover frequency (TOF) and 
exceptional recycling performances. 
 
Figure I-5. Crystal structure, structural components, and underlying network topology of 
PCN-224(Ni). (a) the 6-connected D3d symmetric Zr6 in PCN-224. (b) Tetratopic TCPP 
ligands (violet square) with twisted dihedral angles generate a framework with 3-D 
nanochannels (c). Color scheme: Zr, green spheres; C, gray; O, red; N, blue; Ni, orange; and 
H, white. Reprinted with permission from Ref. 75, copyright © 2013 American Chemical 
Society. 
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PCN-225 constructs from 8-connected Zr6 cluster and TCPP (free base or Zn).77 
Unlike PCN-222 in which the 8-connected Zr6 cluster is D4h symmetry, the cluster in 
PCN-225 adopts D2d symmetry which further reduces the overall symmetry of the 
framework (Figure I-6). PCN-225 represent the first MOFs with (4,8)-connected sqc 
topology. PCN-225 has two types of channels: 0.8 × 1.5 nm2 in quadrangle shape and 0.9 
× 2.2 nm2 pear-like shape. PCN-225 remains structural intactness in aqueous solutions 
with pH = 1-11 as well as boiling water. By taking advantage of the wide pH tolerance of 
PCN-225, the deprotonation of the porphyrin results in fluorescence change, therefore, 
PCN-225 is used as a novel fluorescent pH indicator. 
 
 
 
 
Figure I-6. Structure of PCN-225. (a) Zr6(μ3-O)4(μ3-OH)4(OH)4(H2O)4(COO)8 cluster. The 
oxygen atoms from μ3-OH/-O, OH/H2O and COO groups are shown in green, blue and 
red, respectively. (b) View of the structure of PCN-225 along the b-axis with two types of 
channels. The Zr, O, C, N atoms are shown in pink, red, gray and blue, respectively. H atoms 
are omitted for clarity. Reprinted with permission from Ref. 77, copyright © 2013 American 
Chemical Society. 
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MIL-53 is synthesized by hydrothermal reaction of chromium(III) nitrate and BDC 
ligand with the presence of hydrofluoric acid.70 It is composed of 1D Cr-O infinite chain 
bridged by BDC ligand (Figure I-7). The as-synthesized MIL-53 has 1D channel 
containing unreacted BDC ligand, which can be removed by thermal treatment at 300oC, 
yielding MIL-53ht. MIL-53ht possesses uniform 13.04 × 16.83 Å2 1D channel. MIL-53ht 
adsorbs moisture in air, yielding MIL-53lt, and the pore dimension changes to 7.85 × 
19.69 Å2. This hydration-dehydration induced breathing effect can be ascribed to two 
conjugated phenomena. First, the water molecule forms strong hydrogen bonds with the 
hydrophilic parts of the pore. Second, the π-π interaction between the benzyl groups are 
feasible due to the short ring separation distance (d(C-C) ≈ 3.9-4.5 Å). Remarkably, this 
large breathing phenomenon is fully reversible. 
 
Figure I-7. Temperature variability of MIL-53. (top) Schematic representation of the 
reversible hydration dehydration of MIL-53lt and MIL-53ht. (bottom) X-ray 
thermodiffractogram of MIL-53lt under air; for a better understanding, a 2θ offset is applied 
for each pattern. Reprinted with permission from Ref. 70, copyright © 2002 American 
Chemical Society. 
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MIL-100 is prepared from metallic chromium and 1,3,5-benezenetricarboxylic 
acid (BTC) with the presence of hydrofluoric acid.71 MIL-100 is composed of trimeric-
oxo cluster Cr3(µ3O) connected with BTC ligand, which generates a supertetrahedron 
(STH) with metal cluster on the corner and BTC ligand on the face (Figure I-8). STH then 
connects with each other on a vertex sharing manner to generate MIL-100 structure. 
There are three types of porosities in MIL-100: one microporous cavity (Ø ≈ 6.5 Å), and 
two mesoporous cavities (Ø ≈ 25-30 Å). The smaller mesoporous cavity has a diameter of 
25 Å and is composed of 20 STHs, whereas the larger mesoporous cavity has a diameter 
of 29 Å and is composed of 28 STHs.  
 
 
Figure I-8. Structure and topology of MIL-100. a) The original building block with a trimer 
of metal octahedra chelated by three carboxylic functions. b) The STH formed by using 
trimesic acid, which occupies the faces of STH. c) Ball-and-stick view of a unit cell of MIL-
100. Free water molecules have been omitted for clarity. d) Top: Schematic view of the 3D 
organization of the structure of MIL-100with the medium (green) and large (red) cages 
delimited by the vertex sharing of the STH (the vertices represent the centers of each STH). 
Bottom: View and dimensions of the two different cages (green, 20 STH; red, 28 STH). The 
medium cages share faces and form interconnected rods (in green) in the interstices of which 
are located the large cages. Reprinted with permission from Ref. 71, copyright © 2004 John 
Wiley and Sons. 
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 A similar MOF to MIL-100, MIL-101, is composed of Cr3(µ3O) cluster and BDC 
ligand.72 Similarly, the connection between metal cluster and BDC ligand generates STH 
with cluster on the corner and ligand on the edge (Figure I-9). MIL-101 contains two 
types of mesoporous cavities: the smaller one with diameter of 29 Å with exclusive 
pentagonal windows (Ø ≈ 12 Å), whereas the larger one with diameter of 34 Å with not 
only pentagonal windows but also hexagonal windows (Ø ≈ 15 Å). MIL-101 has one of 
the highest surface areas and pore volume. Owing to its exceptional porosity, large guest 
molecules, such as Keggin polyanions, can be incorporated into the cavity of MIL-101. 
 
Figure I-9. Structure and topology of MIL-101. (A) The computationnally designed trimeric 
building block chelated by three carboxylic functions. The ST was constructed with (B) 
terephthalic acid, which lies (C) on the edges of the ST. (D) Ball-and-stick representation of 
one unit cell, highlighting one ST drawn in a polyhedron mode. (E) Schematic 3D 
representation of the MTN zeotype architecture (the vertices represent the centers of each ST) 
with the medium (in green, with 20 tetrahedra) and large (in red with 28 tetrahedra) cages 
delimited by the vertex sharing of the ST. Chromium octahedra, oxygen, fluorine and carbon 
atoms are in green, red, and blue, respectively. Reprinted with permission from Ref. 72, 
copyright © 2005 American Association for the Advancement of Science. 
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1.3 Enzyme immobilization: principles and applications 
Enzymes are indisputably one of the most important biomacromolecules for life, 
far exceeding artificial catalysts in their ability to efficiently catalyse life-sustaining 
biological transformations.79 Consequently, applying in vivo enzymatic transformations to 
industrial processes is an attractive strategy in order to circumvent the existing laborious 
design and synthesis of artificial catalysts.80 However, such practical applications are 
hindered by enzymes’ fragile nature, such as low thermal stabilities, narrow optimum pH 
ranges, low stabilities towards extreme pH values, low tolerances to most organic 
solvents and many metal ions, etc. Moreover, enzymes themselves are a source of 
contamination in the desired product, resulting in inevitable purification and separation 
steps. Therefore, instead of using enzymes homogeneously, employing heterogeneous 
immobilized enzymes is one of the key strategies for improving the practical 
performances of enzymes.81-83  
The term “immobilized enzymes” refers to “enzymes physically confined or 
localized in a certain defined region of space with retention of their catalytic activities, 
and which can be used repeatedly and continuously”.84 Immobilizing enzymes on solid 
support offers more effective control of the reaction processes and enhanced enzyme 
stability in storage and operational conditions.85 Moreover, the heterogeneous nature of 
the immobilized enzymes provides more facile separation from the product, minimizing 
contamination from the enzymes.86-88 The immobilized enzymes can be recycled to 
reduce the cost of the production processes.86, 89, 90 Besides the potential benefits brought 
by enzyme immobilization, it is important to recognize that the chemical and physical 
properties of an enzyme can suffer changes upon immobilization depending on the choice 
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of immobilization matrix and method.91 Therefore, it is imperative to identify an 
immobilization matrix and technique that cause the smallest loss of enzymatic activity.  
1.3.1 Synthesis of enzyme immobilization materials 
Generally, there are three enzyme immobilization categories: adsorption, covalent 
bonding, and entrapment (Figure I-10).92 The details of each immobilization method will 
be introduced below. 
 
 
 
Figure I-10. Various methods of enzyme immobilization. Reprinted with permission from 
Ref. 92, copyright 2016 © Elsevier Inc. 
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1.3.1.1 Adsorption 
In this method, enzymes adhere to the surface of the matrix by weak interactions 
(hydrogen bonding, hydrophobic interactions, etc.) with the lack of covalent/coordination 
bond formation. Typically, this process involves suspending immobilization matrix in 
enzyme solutions or electrical deposition of enzymes on the electrode surface. Water 
soluble materials, such as polysaccharide derivatives, glass, coconut fibers, kaolin, 
polymers, and cellulose materials, are the commonly used immobilization matrices.93 The 
adsorbed enzymes are usually resistant to proteolytic digestion and self-aggregation 
because of the hydrophobic interaction with the interfaces.94 
Persson et al reported lipase enzyme adsorption on polypropylene-based 
hydrophobic granules/Accurel EP-100.95 They found that reducing the particle size of 
Accurel significantly increased the enantiomeric ratio and reaction rates of immobilized 
lipase. Yarrowia lipolytica lipase immobilized on octyl-agaros and octadecyl-sepa beads 
demonstrated greater stability, higher enzymatic conversion yields, better process control, 
and improved economic effects compared with free lipase.96 This can be attributed to the 
hydrophobic interaction between lipase and the beads. Candida rugosa lipase adsorbed on 
poly(3-hydroxybutyrate-co-hydroxyvalerate) expressed 94% activity even after treating 
for 4 h at 50oC and reusing till 12 cycles.97 Urease enzymes adsorbed on 1,4-butenediol 
diglycidyl ether-activated byssus threads demonstrated increased pH stability and activity 
retaining under dried conditions.98  
1.3.1.2 Covalent binding 
This method depends on the formation of covalent bond between the enzyme and 
the immobilization matrices. Side chain amino acids, such as histidine, arginine, aspartic 
15 
 
acid, may form bonds with matrices. Typically, bond formation takes place when 
activators are present (e.g. carbodiimide compounds).99, 100 When immobilization matrices 
are decorated with peptide on the surface, higher specific activity and stability with 
controlled protein orientation can be achieved.99 Enhanced enzyme stability can also be 
achieved by covalently binding of enzymes onto silica gel carriers that unreacted 
aldehyde groups have been removed beforehand.101  
Cross-linking of the enzyme with immobilization matrices stands for another 
manner of covalent enzyme binding. Glutaraldehyde is a popular cross-linking agent 
owing to its solubility in aqueous solvents and its ability to form inter- or intra-subunit 
covalent bonds. Moreover, cross-linking of enzymes shows improved residual activity 
because of the increased porosity and surface area.102 Zhao et al demonstrated that alcohol 
dehydrogenase enzyme covalently immobilized on attapulgite nanofibers had higher 
thermal tolerance.103 
1.3.1.3 Entrapment 
This method is to non-covalently encapsulate enzymes within a network that 
protect the enzyme while at the same time, the enzyme is accessible to substrates.104 
Experimentally the enzyme encapsulation can be achieved by three strategies: (1) 
inclusion of enzyme within a cross-linked polymer matrix; (2) dissolution of enzyme in a 
nonaqueous phase; (3) separation of enzyme from bulk solution by semipermeable micro-
capsule. Encapsulation with alginate-gelatin-calcium hybrid carriers has been reported to 
increase mechanical stability and prevent enzyme leaching.105 A simultaneous 
encapsulation of lipase and magnetic nanoparticles into biomimetic silica significantly 
increased enzyme activity under various silane additives.106 Lipase encapsulated in κ-
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carrageenan showed high tolerance to organic solvents and heat shock.107 Moreover, 
electrospun nanofibers based enzymatic hybrid materials have shown application 
potentials in biomedicine, biofuel, chemistry, biosensors, etc.108 
1.3.2 Enzyme immobilization matrices 
The materials used for enzyme immobilization, called immobilization matrices, 
should include the following properties. (1) They should be tolerant to the enzyme 
immobilization operational conditions. (2) They should have high enzyme immobilization 
capacity. (3) Any undesirable denaturation induced by the immobilization matrices should 
be excluded.109 Commonly used immobilization matrices are divided into two categories: 
inorganic matrices and organic matrices. 
1.3.2.1 Inorganic matrices 
This category includes glass, silica gel, carbon materials, and metal oxides, by 
taking advantage of their thermal and mechanical resistance.110 Moreover, they are 
resistant to microbial growth and they can provide rigidity and porosity. Details of typical 
materials will be introduced below. 
1.3.2.1.1 Silica 
Silica-based inorganic enzyme immobilization support includes silicon dioxide, 
silicon tetraoxide and zeolite. Silica materials have both hydrophilic and hydrophobic 
sites. They are chemically inert and they need modification and proper activation. A 
typical procedure is to treat silica materials with aminoalkyl triethoxysilanes to introduce 
amino groups to the surface. Penicillin G amidase conjugated with dextran was 
immobilized on amino-modified silica gel and showed increased thermal stability.111 
Another example is lignin peroxidase and horseradish peroxidase immobilized on 
17 
 
activated silica support could remove chlorolignins effectively from eucalyptus kraft 
effluent.112  
1.3.2.1.2 Metal oxide 
Metal oxide, including Al2O3, TiO2, ZrO2, and SnO2, is another type of inorganic 
support because of its porous nature. Candida Antarctica lipase enzyme immobilized on 
metal oxide membrane could carry out hydrolytic and synthetic reactions by restraining 
feedback inhibition.113 Switching membrane to foam support could increase the specific 
surface area and decrease diffusion rates.113 
1.3.2.1.3 Glass 
Glass is highly viscous in nature and has been used as enzyme immobilization 
support. Phthaloyl chloride-containing amino group functionalized glass beads showed 
sustained enzymatic activity when α-amylase was immobilized.92 Urease immobilized on 
glass pH-electrodes served as effective biosensor for blood urea, demonstrating a 
detection level down to 52 mg/mL.114 
1.3.2.1.4 Carbon materials 
This type includes charcoal and activated carbon. Charcoal has been used to 
immobilize amyloglucosidase without cross-linking agents for starch hydrolysis.115 
Activated carbon, typically possessing high surface area and pore volume, has been used 
to immobilize acid protease and acidic lipase that the catalytic activity was well 
maintained even after 21 reusing cycles.116 
1.3.2.2 Organic matrices 
This type of matrix is mainly composed of water-insoluble polysaccharides 
because they are chemically inert and they can bind proteins in reversible and irreversible 
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manners. Alginate is a sulphated polysaccharide obtained from brown algal cell wall. 
Immobilized enzyme gained extra stability when alginate cross-linked with divalent ions 
and glutaraldehyde.117 Chitosan has been widely investigated as enzyme immobilization 
matrix. Enzyme coated with chitosan has less leaching effect compared with 
immobilization on alginate owing to its ionic and physical interactions with the 
enzyme.118 Cellulose is one of the most commonly used enzyme immobilization matrix 
due to its commercially availability. Enzyme immobilized on ionic liquid-cellulose film 
activated with glutaraldehyde showed increased tolerance and feasibility.119 Collagen can 
be a good immobilization platform because it forms covalent bond with enzyme, thereby 
strongly confine the enzyme with the matrix. Catalase immobilized on Fe3+-collagen 
fibers remained activity even after 26 reuses.120 
1.3.3 Applications of immobilized enzymes 
1.3.3.1 Biosensors 
The electrical, chemical, optical, or mechanical devices which can detect 
biological species are called biosensors. An ideal biosensor should be able to detect low 
concentration of a specific analyte in complex samples with quick response time and high 
selectivity. Biosensors based on enzyme immobilization typically possess the above-
mentioned features and can be easily used in stationary or in flow system. A number of 
enzyme immobilized sensors could detect heavy metals in aqueous solutions.121-124 In 
another case, acetylcholinesterase A (AchE) immobilized biosensors could detect toxic 
pesticides.125  
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1.3.3.2 Waste water treatment 
The effluents of a number of industries contain carcinogenic dyes.126 Enzymes 
catalysing redox reactions can play an important role in dye degradations. But due to the 
harsh operational conditions, free enzymes can lose activities very fast. Therefore, 
immobilization can be an ideal strategy. For example, immobilized laccase can degrade 
various dyes, such as anthracinoid dye, lancet blue, etc.127 
1.3.3.3 Biodiesel production 
Biodiesel is a liquid fuel produced by triglycerides and esterification of alcohol in 
the presence of catalyst. However, the production of traditional catalyst consumes huge 
energy. Using enzyme immobilized catalyst can reduce the energy consumption, as 
demonstrated in a case which immobilized lipase was involved.128 
1.4 Enzyme immobilization on MOFs: advantage over free enzyme 
Owing to the exceptional tunability of MOF structure, pore size, shape and 
environment, enzyme immobilization on MOFs have received extensive attention in the 
past decade. Typical preparation methods of enzyme-MOF composites include surface 
attachment, pore encapsulation, covalent linkage, and one-pot 
coprecipitation/biomineralization. Many of these are very similar to Section 1.3.1. 
Examples of enzyme-MOF composites are summarized in recent reviews.129 Below only 
the advantage of MOF-immobilized enzymes over their free counterparts will be 
introduced. 
1.4.1 Reusability 
One of the greatest advantages immobilized enzymes have over free enzymes is 
their recyclability, which significantly reduces costs. Moreover, immobilized enzymes 
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show a significantly lower proportion of impurities resulting from product contamination 
when compared to free enzymes. Enzymes anchored by robust covalent bonds to MOF 
matrices, such as trypsin–MIL-88B, are able to maintain their catalytic performances, 
showing a negligible activity loss even after 4 cycles.130 Besides covalent linkages 
between enzymes and MOFs, weak interactions also considerably improve the reusability 
of the immobilized enzymes. 
As evidenced in the case of BSL2@HKUST-1, MOF–enzyme host–guest 
interactions improve the reusability of immobilized enzymes.131 Substrate conversion 
after 10 cycles did not demonstrate any substantial drop, which indicates that BSL2 was 
stabilized by the planar BTC ligand of the MOF through hydrophobic interactions. 
In many pore encapsulation cases, using MOFs with pore windows smaller than 
the size of the enzyme prevents leaching of the enzyme, which significantly contributes to 
the exceptional reusability of the composite. In composites made with Tb-meso-MOFs, 
MP-11@Tb-mesoMOF maintained its activity over 6 cycles, while Mb@Tb-mesoMOF 
maintained activity over 15 cycles without a significant drop.132, 133 In another case, at 
 
 
Figure I-11. Catalytic activity of immobilized enzymes in each recycle test. Reprinted with 
permission from Ref. 129, copyright 2017 © Royal Chemical Society. 
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least 80% activity of HRP was retained within 5 cycles when it was immobilized on a 
mesoporous MOF, PCN-333. On the contrary, HRP immobilized on SBA-15 lost more 
than 70% activity in the first cycle (Figure I-10).134  
Dye tagging on enzymes can also improve the reusability of the immobilized 
enzymes. Trypsin–FITC@CYCU-4 maintained more than 80% activity after 3 to 5 
cycles. The recyclability can be attributed to the specific host–guest interactions between 
FITC and CYCU-4's micropores and the confinement of trypsin within CYCU-4's 
mesopores.135 In contrast, unmodified trypsin immobilized on CYCU-4 demonstrated a 
significant drop in activity after the first cycle. Moreover, size matching of the dye 
molecule and the MOF cavity significantly improves the reusability of dye tagged MOF–
enzyme composite. As an illustration, trypsin–NBD@UiO-66 demonstrated almost 100% 
 
 
Figure I-12. BSA proteolytic efficiency of trypsin–NBD@UiO-66, trypsin–FITC@UiO-66 and 
trypsin@UiO-66. Reprinted with permission from Ref. 129, copyright 2017 © Royal 
Chemical Society. 
 
 
22 
 
activity after 5 cycles of BSA digestion due to the size compatibility of NBD molecule 
with the microporous cavities of UiO-66, whereas trypsin–FITC@UiO-66 lost more than 
half of its activity by the 5th cycle, a result of the incompatible size interaction between 
the small MOF pore and the large FITC molecule (Figure I-11). 
1.4.2 Catalytic activity 
Many MOF–enzyme composites demonstrate enhanced catalytic activities when 
compared with the free enzymes. This is evidenced by improved conversion rates and 
percentages, which are typically ascribed to: (1) single enzymes are confined by MOF 
cavities; (2) functional groups on the MOF backbones are actively involved in the 
catalytic processes. Additionally, the size of the pore opening can render unusual size 
selectivity to MOF immobilized enzymes. 
In many cases, immobilization prevents undesirable enzyme self-aggregation, 
which usually results in slow conversion rates or poor yields. In MP-11, the aggregation 
significantly reduces the accessibility of the heme moiety, thus adversely affects its 
activity. Upon immobilization on Cu–MOF and Tb-mesoMOF, MP-11 demonstrated 
increased conversion percentages of 10 and 4 times respectively. The same effect was 
observed for BSL2@HKUST-1, whose initial rate was 18 times that of the free BSL2.131  
The functionalities of MOFs can affect the activities of immobilized enzymes 
through hydrophilic/hydrophobic interactions. For example, the conversion percentage of 
PPL@UiO-66-NH2 demonstrated 11% lower than PPL@UiO-66, whereas PPL 
immobilized on carbonized MIL-53(Al) demonstrated a 5% activity enhancement 
compared to PPL@MIL-53(Al).136 This result indicates that the hydrophobicity of UiO-
66 and carbonized MIL-53(Al) are favourable for the adsorption of the hydrophobic 
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lipase onto the MOF's surface, thus leading to higher activity. In another case the BSA 
hydrolysis activity of trypsin immobilized MIL-88B-NH2 was 2 times more than that of 
trypsin immobilized MIL-88 or MIL-101. The authors claimed that the hydrophilic amino 
groups on the surface of MIL-88B-NH2 reduced undesired non-specific BSA–MOF 
interaction and enhanced the interaction between BSA and immobilized trypsin through 
hydrogen bonding. 
Furthermore, the size incompatibility of large substrates with relatively small 
apertures of MOFs can result in restricted substrate diffusion into the MOF cavity, 
allowing for substrate selectivity in the immobilized enzymes. The first size selective 
catalysis for Mb was achieved by Mb@Tb-mesoMOF.133 The initial rate for THB was 
almost 6 times faster than that for ABTS in Mb@Tb-mesoMOF mediated conversions, 
and was more than double the rate of catalysis by free Mb and Mb@SBA-15. The large 
ABTS molecule, with dimensions of 1.01 × 1.73 nm2, was unable to enter the small pore 
(0.9 nm) of Mb@Tb-mesoMOF. However, the small THB molecule (0.57 × 0.58 nm2) 
could feasibly approach immobilized Mb via diffusion through the pores. 
1.4.3 Stability 
Enzyme denaturation occurs when enzymes are exposed to extreme pH, extreme 
temperature, or organic solvents. These external stresses can alter the conformation of 
enzymes, which results in the loss of enzymatic activity due to the deformation of the 
active site. The physical immobilization of enzymes on MOFs minimizes the loss of 
enzymatic conformation under these conditions, thus enhancing the enzymes' tolerance to 
denaturation conditions. A covalently immobilized SEH–MOF composite, SEH@UiO-
66-NH2, demonstrated an activity enhancement of 60% at pH 8.5 and 75% at 45 °C 
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compared with free SEH. This is most likely owing to the stabilization of the enzymes 
provided by cross-linking with MOF supports. In OPAA@PCN-128y, its activity could 
be retained after treatment at 70 °C or 3 days dry storage, while free OPAA could only 
survive at 45 °C or 1 day after lyophilisation.137 A HRP@ZIF-8 composite could maintain 
85% activity under boiling water or boiling DMF treatment. This result is unprecedented 
in enzyme immobilization on other materials (Figure I-12).138 Lipase entrapped in ZIF-8 
demonstrated exceptional stability under various denaturation conditions.139 The activity 
 
Figure I-13. The resistance of free or immobilized enzymes towards perturbations. Product 
conversion of free HRP, the biomimetically mineralized ZIF-8 using HRP (ZIF-8/HRP), HRP 
protected by calcium carbonate (CaCO3/HRP) and HRP protected by mesoporous silica 
(SiO2/HRP, SiO2 with average pore size of 7, 20, 50 and 100 nm) in the presence of proteolytic 
agent, trypsin, after treatment in boiling water for 1 h, and after treatment in boiling DMF for 1 h 
at 153 °C, respectively. Data were normalized against free HRP activity at room temperature. 
Error bars represent the s.d. of three independent experiments. Reprinted with permission from 
Ref. 129, copyright 2017 © Royal Chemical Society. 
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enhancement of the composite over free enzyme was more than 40% with 1 mM 
Zn2+ treatment, 30% at 85 °C, and 60% at 50 °C treated for 50 minutes.  
Trypsin digestion is another important denaturation route for in cellulo or in 
vivo enzyme applications. The small apertures of MOFs can prevent the entry of trypsin 
and avoid undesired digestion, which is important to the preservation of enzymatic 
activity. A bi-enzyme immobilized ZIF-8 composite maintained more than 90% of its 
activity after treated with 1 mg mL 1 trypsin for 30 minutes at 37 °C while the free 
enzymes lost more than 50% of its activity under the same treatment.140 A similar 
protective effect was observed for a mesoporous MOF, PCN-888, with almost all activity 
maintained after 60 minutes of trypsin treatment.141  
1.5 Summary 
Enzyme immobilization has attracted extensive attention owing to the improved 
performances, especially in harsh ex vivo conditions, compared with free enzymes. 
Traditional matrices, although demonstrating promising performances in some cases, are 
hindered by intrinsic shortcomings. For example, sol–gel matrices are intrinsically porous 
and can prevent enzyme leaching due to entrapment. However, the entry of bulky 
substrates into these pores is sometimes restricted.142 Moreover, enzyme immobilization 
takes place during sol–gel synthesis which may lead to enzyme denaturation. Enzymes 
immobilized in hydrogels or organic microparticles suffer from leaching (owing to the 
swelling or degradation of the matrices), enzyme denaturation, and restricted mass 
transfer.143-145 Mesoporous silica, bearing large surface area and pore volume, have 
attracted much attention.146-148 However, the challenges of rational structural design, 
leaching of enzymes from the support, and surface charges that promote enzyme 
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denaturation or reduction of enzyme loading hinder the use of mesoporous silica as an 
enzyme support. MOFs can be novel platforms for enzyme immobilization owing to (1) 
extraordinary tunability in structure, pore size, shape, and environment; (2) permanent 
porosity that allows for substrate and product diffusion; (3) feasible modification on the 
surface to achieve selective accumulation in in vivo applications; (4) robustness in 
aqueous conditions that protect vulnerable enzymes against perturbation.  
Besides the numerous works that have demonstrated the enzyme encapsulation 
capability of MOF matrices, operating MOF–enzyme composites in biomedical 
conditions has been rarely reported. As this could lead to novel strategy for life-sustaining 
technologies, such as enzyme replacement therapy or enzyme supplement therapy, it is 
highly desirable to study the performance of MOF-enzyme composites in cell culture and 
animal model level before taking into account of pre-clinical applications and clinical 
trials. Several MOF–enzyme composites demonstrate retention of enzymatic activities 
under trypsin digestive pressure, indicating that they might be able to serve as 
transportation vehicles for enzyme replacement therapy in vivo, as free enzymes are 
rapidly eliminated from the circulatory system.149 The enantiomeric selectivity 
demonstrated by MOF–enzyme composites also prove beneficial to the pharmaceutical 
industry, where selectivity is vital due to significant differences in biological activities of 
enantiomers. More application-based studies need to be conducted in order to optimize 
the MOF–enzyme composites for more specific functions. In addition, the facile post-
synthetic modification amenability of MOFs allows for the development of highly 
targeted systems.150, 151 Overall, although only proof-of-concept studies are accomplished 
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on this novel composite, the development of MOF–enzyme composites has shown huge 
potential, providing a springboard for further development. 
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CHAPTER II 
THE PREPARATION OF AN ULTRASTABLE MESOPOROUS CR(III)-MOF VIA 
REDUCTIVE LABILIZATION2 
2.1 Introduction 
Bearing the high surface area, large pore size and volume as well as the tunability 
of pore environments and functionalities, metal-organic frameworks (MOFs) have 
demonstrated promising applications in storage, separation, catalysis, guest moiety 
immobilization, drug delivery and sensing.38, 152-154 Many of these applications include the 
use of metal nodes, or secondary building units (SBUs), as active sites. SBUs are always 
explored as Lewis acid species, while their redox properties have been studied in only a 
few reports.155, 156 One of experimental demonstrations is the reduction of high valence 
Fe(III) to generate low valence Fe(II) in MIL-100-Fe(III) by carbon monoxide, indicating 
the possibility of tuning the chemical robustness of the framework by redox reaction.155 
Based on the Hard and Soft Acid and Base (HSAB) Theory,69 chemically robust 
MOFs can be constructed with carboxylate ligand, defined as a hard Lewis base, and high 
valence metal ions, such as Fe(III), Cr(III) or Zr(IV), categorized as hard Lewis acids. 
Compared with MOFs composed of divalent species, many of these high valence metal 
containing MOFs can survive in water, or even acid or base solutions. This phenomenon 
has been exclusively demonstrated in MIL series, UiO series and PCN-22X series.16, 72, 73, 
78, 157-163A recent example is an iron based mesoporous MOF, PCN-333-Fe(III), which is 
stable in both acidic and basic aqueous solutions despite its ultrahigh porosity.134 
2 Reproduced with permission from “The preparation of an ultrastable mesoporous Cr(III)-MOF via reductive 
labilization” by Lian, X.; Feng, D.; Chen, Y.-P.; Liu, T.-F.; Wang, X.; Zhou, H.-C. Chem. Sci., 2015, 6, 7044-7048, 
copyright 2015 by Royal Society of Chemistry. 
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However, MOFs constructed with high valence metal ions may suffer from structure 
breakdown in some specific environments, for instance, PCN-333-Fe(III) totally loses its 
crystallinity and porosity in alkylamine solution. Incorporation of kinetically inert metal 
ions, for example, Cr(III), into the framework backbone could generate MOFs with 
exceptional stability.72, 164 
Nevertheless, obtaining crystalline Cr(III)-MOFs with carboxylate ligands are 
extremely difficult due to the inertness of Cr(III). Hydrothermal conditions are exclusive 
adopted in the synthesis of crystalline Cr(III)-MOFs, but these conditions might be 
unfeasible for larger organic ligands as they are extremely hydrophobic. Synthetic 
attempts of PCN-333-Cr(III) by either hydrothermal or solvothermal conditions with 
temperature as high as 220oC failed to generate any crystalline products. An alternative 
synthetic pathway is post synthetic metathesis of metal clusters from a template MOF 
with a known structure. Fe(III)-MOFs can serve as practical structural templates because 
iron resembles chromium in both coordination geometry and valence.  Disappointingly, 
metathesis of PCN-333-Fe(III) with CrCl3 for 24 hours only yielded partially 
metathesized MOF. The incompleteness of the above metathesis is not surprising since in 
several reports demonstrating the feasibility of metal metathesis for thermodynamically 
inert MOFs, complete metal metathesis has never been achieved.162 This is mainly 
contribute to two reasons: (a) the dissociation of high valence metal ions from framework 
is thermodynamically unfavorable; (b) the dissociation rate of high valence ions is much 
slower than that of the divalent species due to the much higher activation energy. 
Therefore, long reaction time or elevated reaction temperature is required in order to 
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achieve complete metathesis. However, under these scenarios, framework decomposition 
is usually inevitable due to the acidic environments generated by high valence species.165 
Herein, we report a reductive labilization-metathesis route for the synthesis of 
PCN-333-Cr(III) with PCN-333-Fe(III) as the template, wherein redox chemistry has 
contributed to the generation of labile metathesis intermediates. PCN-333-Cr(III) 
demonstrated broader range of applications than PCN-333-Fe(III) in consequence of its 
improved chemical sustainability. The alkylamine incorporated PCN-333-Cr(III) 
demonstrated significant CO2 adsorption capacity under low pressure whereas PCN-333-
Fe(III) barely shows any CO2 adsorption capacity due to structural decomposition in 
alkylamine solution. 
 
2.2 Experimental Section 
2.2.1 Materials and Instrumentation 
Materials 
Iron(III) chloride anhydrous (FeCl3), anhydrous AlCl3, cyanuric chloride, MgSO4, 
chromium(II) chloride anhydrous (CrCl2), chromium trioxide, sulfuric acid, acetic acid, 
acetic anhydride, toluene, chloroform, N,N-dimethylformamide (DMF), N,N-
diethylformamide (DEF), methanol, trifluoroacetic acid (TFA) were purchased from Alfa 
Aesor. All commercial chemicals were used without further purification. 
Instrumentation 
Powder X-ray di raction (PXRD) was carried out with a BRUKER D8-Focus 
Bragg Brentano X-ray powder di ractometer equipped with a Cu sealed tube (λ = 
1.54178Å) at 40 kV and 40 mA. Thermogravimetric analyses (TGA) were conducted on a 
31 
 
TGA-50 (SHIMADZU) thermogravimetric analyzer. Gas sorption measurements were 
conducted using a Micrometritics ASAP 2420 system at various temperatures. Inductively 
Coupled Plasma Emission - Mass Spectrometry (Laser Ablation) was carried out by 
Perkin Elmer DRCII ICP-MS with both solution and laser ablation capabilities. 
2.2.2 Ligand Synthesis 
Step 1. Synthesis of 2,4,6-tri-p-tolyl-1,3,5-triazine 
 
 
Scheme II-1 Synthesis of 2,4,6-tri-p-tolyl-1,3,5-triazine 
 
20 g anhydrous AlCl3 was added into a 250 mL three-connected flask containing 
50 mL dry toluene. The temperature is increased to 60oC under inert atmosphere. 8.3 g 
cyanuric chloride was added in three portions and the mixture was allowed to stir for 1 
hour. The resulting red sticky oil was then cooled down and poured into 500 mL ice water 
mixture to terminate the reaction. The aqueous phase was extracted with chloroform for 
three times. The organic phases were combined and dried with MgSO4. Methanol was 
added into the organic phase and the mixture was allowed to stay in 4oC fridge for 
overnight. The resulting solid was collected by filtration and was recrystalized from 
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refluxing toluene to afford white needle-like crystalline product. 1H NMR (300 MHz, 
CDCl3): δ = 2.46 (s, 9 H), 7.35 (d, 6 H), 8.64 (d, 6 H). 
Step 2. Synthesis of H3TATB 
 
 
Scheme II-2 Synthesis of H3TATB 
 
2.78 g 2,4,6-tri-p-tolyl-1,3,5-triazine was dissolved in 70 mL acetic acid. Then 4.4 
mL concentrated sulfuric acid and 4.8 mL acetic anhydride was added and the mixture 
was stirred at 0oC. 7.2 g chromium trioxide was added and the mixture was stirred at 
room temperature for 12 h. 300 mL ice cold water was added to quench the reaction and 
the solid was filtrated. The solid was dissolved in 200 mL 2M NaOH solution. The 
unreacted material was removed by filtration. The clear greenish solution was then 
acidified with 10% HCl solution to give white crude product (until pH<3). The crude 
product was filtered, dried, and purified by recrystallization from reflux DMF. The pure 
product was a white crystalline solid. 1H NMR (300 MHz, DMSO): δ = 8.20 (d, 6 H), 
8.85 (d, 6 H), 13.35 (s, 3 H). 
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Step 3. Synthesis and activation of PCN-333-Cr(III) 
FeCl3 (60 mg), H3TATB (60 mg), DEF (10 mL) and TFA (0.5 mL) were mixed in 
a 20 mL vial. The solids were supersonically dissolved and the vial was heated at 150oC 
for 12 hours. The resulting solid was centrifuged and washed with anhydrous DMF for 
several times. 10 mL of anhydrous DMF was added into the vial and the mixture was 
degassed with nitrogen for 2 hours. 120 mg CrCl2 was added into the vial in a glove box. 
Then the vial was heated at 85oC for about 30 minutes until all of the solids turned green. 
Then the vial was centrifuged and transferred into the glove box to discard the mother 
liquor followed by rinsing with anhydrous DMF for three times. The vial was taken out of 
the glove box and rinsed with DMF twice in the air. For sample activation, the sample 
was rinsed with acetone twice, dried at 85oC and activated at 150oC for 5 hours. 
Step 4. Stability test 
60 mg solid was suspended in 10 mL aqueous solution at different pH values for 
24 hours under room temperature. The solid was collected by centrifuge and was rinsed 
by acetone three times, dried at 85 oC, and activated at 150 oC for 5 hours. 
Step 5. Preparation of PEI-incorporated PCN-333-Cr(III) and PEI-incorporated PCN-333-
Fe(III) 
60 mg activated PCN-333-Cr(III) was suspended in anhydrous dichloromethane (5mL) 
and 300 mg PEI was slowly added in the slurry. The mixture was well mixed by gentle shaking 
for 20 minutes. The solid was separated by centrifuge and the excess PEI was washed by 
dichloromethane. The sample was first dried under vacuum and activated at 80 oC for 1 hour. 
PEI-incorporated PCN-333-Fe(III) was obtained in the same manner as PEI-incorporated PCN-
333-Cr(III). 
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2.3 Results and Discussion 
MOFs constructed with divalent metal ions have been demonstrated to be good 
templates for complete metal metathesis due to the thermodynamic and kinetic lability of 
their coordination bonds.10, 165-171 The reduction of high valence metal in SBUs can 
labilize the robust MOF, which will provide possibility for complete metathesis with a 
robust MOF template. There are several prerequisites for this process to take place: (1) 
the metal ions of the framework are in their high oxidation state and can be readily 
reduced under mild condition; (2) the reductant will not cause harsh conditions after 
oxidation (for example, very low/high pH values); (3) the oxidation potential of the 
oxidant is much higher than the reduction potential of the reductant, resulting in an 
irreversible redox reaction. In the practical case, PCN-333-Fe(III) is composed of 
 
 
Figure II-1. Structure and cavity of PCN-333. (a) PCN-333 is composed of trimeric clusters 
and TATB ligands with (b) supertetrahedron as supermolecular building blocks. (c) The small 
cage with diameter of 4.2 mm and (d) the large cage with diameter of 5.5 nm. 
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oxidative Fe(III) species while CrCl2 matches the prerequisites to be a suitable reductant. 
The M3+/M2+ redox potentials for Fe and Cr in aqueous solutions are: 0.77V (Fe), -0.42V 
(Cr).172 The large potential difference indicates that redox reaction can irreversibly take 
place between Fe(III) and Cr(II) as indicated in eq. (1): 
     +	    	→ 	     +	    	        (1) 
Driven by the concentration gradient, the metal metathesis between Fe(II) in the 
intermediate framework and Cr(II) in the solution is thermodynamically and kinetically 
favorable. 
Freshly prepared PCN-333-Fe(III) was dispersed in a solution of CrCl2 in dry N,N-
dimethylformamide (DMF) at 85oC under the protection of N2. The color of the solid 
turned gradually from reddish brown to deep green (Figure II-2). The complete metathesis 
of Fe by Cr was obtained after 30 minutes as confirmed by inductive coupled plasma 
mass spectroscopy (ICP-MS) and energy-dispersive X-ray spectroscopy (EDS) (Figure II-
 
 
Figure II-2. SEM-EDS analysis of PCN-333-Cr(III). (A) The EDS spectrum of PCN-333-
Cr(III); (B) PCN-333-Fe(III) on the left and PCN-333-Cr(III) on the right; (C) SEM images 
of PCN-333-Cr(III); elemental mappings of (D) C, (E) Cr, and (F) O from EDS analysis on 
PCN-333-Cr(III). 
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2, Table II-1). The SEM-EDS mapping with 4,000,000 counts results indicated that Cr, C, 
O and Cl were uniformly distributed on the crystal surface (Figure II-2). After that, the 
solids were washed with DMF three times in the air exposure to guarantee that all of the 
Cr(II) ions in the framework were oxidized to Cr(III), which was verified by X-ray 
photoelectron spectroscopy (XPS). The crystallinity of the metathesized product was 
maintained and recognized to be isostructural with PCN-333-Fe(III) as shown in the 
powder X-ray diffraction patterns (Figure II-3). The surface area and porosity of the 
metathesized product was also preserved based on the isotherms of N2 adsorption 
measurements (Figure II-3). This reaction condition is optimum since higher or lower 
temperature with longer or shorter reaction time will either yield partially metathesized 
material or cause structure decomposition and porosity loss. 
The reductive labilization-metathesis process was facilitated in the PCN-333 system for 
several structural characteristics. First, the microcrystalline and mesoporous nature of 
PCN-333 allows the metal ions to diffuse efficiently into the inner cavity of the 
framework. Besides, the trimeric clusters in PCN-333 are able to accommodate both di- 
and trivalent metal ions by varying charges of the terminal ligands, the bridging oxygen 
atoms, and/or the number of counterions.162 Furthermore, the usage of the anhydrous 
reaction solvent decelerated the hydrolysis of Cr(III) species. The absence of acidic 
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condition contributes to the structural intactness of the intermediate MOF composed of 
fragile Cr(II)-O bond.  
 
 
Table II-1. ICP-MS results of each metathesis.  
Metal salt Template Temperature /oC Reaction time (h) M1 : M2 
CrCl2 PCN-333(Fe) 85oC 0.5 Cr : Fe 
12: 1 
CrCl3 PCN-333(Fe) 150oC 12 Cr : Fe 
3.44: 1 
CrCl2 PCN-333(Sc) 85oC 12 Cr : Sc 
1 : 2.26 
 
 
In order to exclude the possibility that the metathesis of PCN-333-Fe(III) with 
CrCl2 circumvented the reductive labilization mechanism, a redox inert isostructural 
framework PCN-333-Sc was synthesized as a template to metathesize with CrCl2. If the 
Cr(II) species were hypothesized to metathesize with Fe(III) ions in the framework 
directly without undergoing redox reaction, complete metal metathesis should also be 
observed in the system of PCN-333-Sc and Cr(II) since the Sc(III)-O coordination bond is 
not as robust as the Fe(III)-O bond. The mixture of PCN-333-Sc and CrCl2 in dry DMF 
was heated at 85oC for 30 minutes. The EDS results showed that only one fifth of the 
scandium in the framework was exchanged with chromium (Table II-1). This observation 
suggests that the metathesis between PCN-333-Fe(III) and CrCl2 should undergo 
reductive labilization-metathesis manner since a thermodynamically more labile 
38 
 
framework failed to generate complete metathesized product without reductive 
labilization. 
According to Marcus Theory and some calculation results, the electron transfer 
between Fe(III) and Cr(II) in this case should undergo outer-sphere mechanism although 
the experimental evidence of this mechanism is still pursuing in our group. First of all, 
inner-sphere mechanism requires the dissociation of axial ligands from Fe(III) whereas 
outer-sphere mechanism does not include coordination bond dissociation. Since the 
dissociation of Fe(III)-ligand bond is thermodynamically and kinetically unfavorable, 
outer-sphere electron transfer mechanism is more reasonable. Moreover, based on 
calculations, the rate constant of the cross redox reaction between Fe(III) and Cr(II) in 
aqueous solution is nearly 3×107 M-1 S-1, which is close to the rate constant of the well-
known outer-sphere redox couples, for example, [Fe(phen)3]2/3+ (1.5×107 M-1 S-1), and 
 
 
Figure II-3. N2 isotherms (top) and PXRD patterns (bottom) of PCN-333-Fe(III), PCN-333-
Cr(III), PCN-333-Cr(III) treated with water, pH = 0 and pH = 11.0 aqueous solutions for 24 
hours. 
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much larger than the well-known inner-sphere redox couples, for example, 
[Cr(H2O)6]2++[Co(NH3)5Cl]2+ (1.46×10-2 M-1 S-1).173 The metal ions are still in high-spin 
electronic configurations and their coordination field splittings in the framework or in the 
DMF solutions are similar to those in aqueous solutions which indicates that outer-sphere 
electron transfer is expected between these two metal ions. The calculation details are 
listed below: 
 
k   = (k  k  K  f  )
 / 			f   =
(logK  )
 
4log	
k  k  
Z 
≈ 1 
kAB = rate of cross reaction; kAA, kBB = self-exchange rates; KAB = equilibrium constant of 
reaction; Z = collision frequency for hypothetical uncharged complex (10  -10  	M   s  ). 
 
k   ≈ (k  k  K  )
 / 	 
Fe   + Cr  	→ Fe   +	Cr   
Fe   + e 	→ Fe  				E  = 0.77	V 
Cr   + e 	→ Cr  				E  =	 0.40	V 
Fe   + Fe  	→ Fe   +	Fe  					k   = 4.5	M
  s   
Cr   + Cr  	→ Cr   +	Cr  					k   = 1 × 10
  		M   s  	 
G  = RTlnK 
G  = nF E  
RTlnK= nF E 			K= e
     
    
K   = e
  .  ( .    .  )= 1.92 × 10   
k   = (1.92 × 10
   × 4.5 × 1 × 10  	) /  = 2.94 × 10 	M   s   
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As expected, the chemical stability of PCN-333-Cr(III) was much enhanced 
compared with PCN-333-Fe(III). Suspended in water, HCl aqueous solution (pH = 0) and 
NaOH aqueous solution (pH = 11.0) at room temperature for 24 hours, PCN-333-Cr(III) 
maintained structural integrity without appreciable loss of crystallinity as confirmed by 
PXRD measurements (Figure II-3). In contrast, PCN-333-Fe(III) was only stable in 
aqueous solutions at pH ranging from 3.0 to 9.0. To demonstrate the intactness of 
porosity, N2 isotherms were conducted before and after each treatment. The results 
indicated that the void volume accessibility, the characteristic mesoporous adsorption 
patterns and the pore size distributions of PCN-333-Cr(III) after each treatment was 
unequivocally preserved. Remarkably the samples after each treatment even showed 
higher total adsorption amount than the as-prepared PCN-333-Cr(III). That is probably 
because some insoluble Cr(III) compounds, generated during metal metathesis and 
trapped in the pores, were removed upon the above-mentioned treatments.  
The above results have clearly demonstrated that employing kinetically inert metal 
ions is an efficient strategy for constructing ultrastable MOFs with high porosity. Since 
the association-dissociation equilibrium of metal-ligand coordination bond always exists, 
coordination bonds in a MOF also undergo association-dissociation process. In the 
aqueous solution, carboxylate ligand substitution around metal ions with other ligands 
 
 
Scheme II-3. Characteristic lifetimes for exchange of water molecules in trivalent aqua 
complexes.  
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from the solution, for example, water or hydroxyl group, may take place, which could 
lead to the breakdown of MOF structure. For two metal ions with the same valence, 
ligand substitution rate of the kinetically inert species is far slower than that of the labile 
counterpart.172 As shown in Scheme II-3, the ligand exchange rate of Cr(III) in aqueous 
solutions is more than 1010 times slower than that of Fe(III) species, which is believed to 
be the key factor that contribute to the superior chemical stability of Cr(III)-MOFs 
compared with other MOFs based on trivalent species. Meanwhile, the slow Cr-ligand 
dissociation rate also decreases the hydrolysis rate of the carboxylate ligand which also 
contributes to the improvement of MOF stability. 
By taking advantage of the superior chemical stability of PCN-333-Cr(III), 
alkylamine was incorporated in PCN-333-Cr(III) aiming to improve the CO2 adsorption 
capacity. Branched polyethylenimine (PEI, Mw = 800) was selected for the high density 
 
 
Figure II-4. (a) CO2 adsorptions of PEI-incorporated PCN-333-Cr(III) and PEI-incorporated 
PCN-333-Fe(III). (b) PXRD patterns of PEI-incorporated PCN-333-Cr(III) and PEI-
incorporated PCN-333-Fe(III). 
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of amine groups on each molecule. After PEI treatment the solid maintained its 
crystallinity with CO2 adsorption capacity of 8.4 wt% at 1 bar (Figure II-4). In contrast, 
PCN-333-Fe(III) completely lost its crystallinity and porosity after PEI treatment 
according to the PXRD pattern and N2 adsorption measurement (Figure II-4). 
 
2.4 Conclusion 
In conclusion, we reported a reductive labilization-metathesis route for the 
construction of an ultrastable mesoporous Cr(III)-MOF from a robust iron-based MOF 
template. The involvement of redox chemistry has switched a thermodynamically and 
kinetically forbidden process into a feasible one. The whole process includes (1) 
reduction of Fe(III) on the framework backbone to Fe(II); (2) metal metathesis between 
Fe(II) and Cr(II); (3) oxidation of Cr(II) in the framework to Cr(III). The presence of 
Fe(II) intermediate was proved by incomplete metathesis of PCN-333-Sc exchanged with 
CrCl2. After metathesis, PCN-333-Cr(III) has demonstrated unprecedented chemical 
stability in aqueous solutions at pH 0 to 11.0 whereas PCN-333-Fe(III) can only survive 
in solution at pH 3.0 to 9.0. Significantly, PCN-333-Cr(III) is robust enough to bear the 
harsh condition of alkylamine solution, displaying high CO2 adsorption capacity after PEI 
incorporation. Overall, the method we represent here demonstrated a new platform to 
synthesize ultrastable MOFs with high porosity for practical applications. 
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CHAPTER III 
COUPLING TWO ENZYMES INTO A TANDEM NANOREACTOR UTILIZING A 
HIERARCHICALLY STRUCTURED MOF3 
3.1 Introduction 
During the course of evolution, nature has developed an ingenious series of multi-
enzymatic systems to catalyze cascade reactions in the microenvironment of a cell.174 In 
mitochondria, for instance, eight enzymes are involved in the citric acid cycle, catalyzing 
a controlled metabolism of sugars, fats and proteins and a highly effective production of 
ATP with minimal consumption of energy.174-176 Inspired by the biosynthetic efficiencies 
of nature and in the search for more sustainable alternatives to today's ways of producing 
chemicals, scientists have tried to couple multiple enzymes for synthesis in a cascade 
manner.174, 177  Specifically, in order to prevent the fragile enzymatic catalytic processes 
from undesired or toxic conditions, various enzymatic cascade nanoreactors have been 
developed based on porous materials such as phospholipid liposomes, polymersomes and 
mesoporous silica.178-182 Although they demonstrated enzymatic reactivity, their catalytic 
performances were still far from satisfactory for any real applications. A major problem is 
that a high enzyme encapsulation capacity, which is critical to fulfill their desired 
functions, is not achievable in these materials.179 Furthermore, the weak mechanical 
stability of liposomes, the poor permeability of the polymersome membrane and the 
severe enzyme leaching from mesoporous silica materials in cyclic uses are limiting 
3 Reproduced with permission from “Coupling two enzymes into a tandem nanoreactor utilizing a hierarchically 
structured MOF” by Lian, X.; Chen, Y.-P.; Liu, T.-F.; Zhou, H.-C. Chem. Sci., 2016, 7, 6969-6973, copyright 2016 by 
Royal Society of Chemistry. 
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factors due to the nature of the materials.134, 181 Therefore, searching for more promising 
materials for enzyme encapsulation and coupling is highly desirable. 
Metal–organic frameworks (MOFs) are an emerging class of porous materials with 
a vast application potential.38, 133, 153, 156, 183, 184 It has been established that cage-containing 
MOFs (cageMOFs) always act as efficient molecular traps affording strong interactions 
between the framework and the encapsulated moieties;132, 138, 154, 185-192 especially in one 
case single enzyme encapsulation was achieved in a hierarchical mesoporous MOF, 
leading to a record high enzyme encapsulation capacity and excellent catalytic 
performances.134 In this work the same design approach is applied to deal with a much 
more sophisticated problem—coupling two enzymes in a tandem manner with a precise 
control of the distribution of each enzyme in the nanoreactor. To achieve this aim, a novel 
hierarchical mesoporous MOF, PCN-888, which contains three types of cages with 
different sizes, is rationally designed and synthesized. The largest cage of PCN-888 
accommodates one GOx while the medium cage accommodates one HRP. A stepwise 
encapsulation with a specific encapsulation order (GOx first, then HRP) is a key 
operation to achieve the bi-enzyme coupling in PCN-888. The smallest cage is too 
compact for either enzyme, thus it is left empty as a diffusion pathway for substrates and 
products. PCN-888 demonstrates not only a very high enzyme loading but also a 
negligible enzyme leaching, whereas the catalytic activity of the encapsulated enzymes is 
well maintained. Moreover, this nanoreactor shows a convincing reusability and 
outstanding stability against the digestion of trypsin, indicating its potential applications 
for in vitro or in vivo studies. 
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3.2 Experimental Section 
3.2.1 Materials and Instrumentation 
Aluminum chloride hexahydrate (AlCl3.6H2O), anhydrous aluminum chloride, 
chromium(VI) oxide (CrO3), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
diammonium salt (ABTS) and N,N-diethylformamide (DEF) is purchased from Alfa 
Aesar. Phosphorous pentachloride (PCl5), phosphorous oxochloride (POCl3), glucose and 
horseradish peroxidase (HRP) is purchased from Sigma Aldrich. Glucose oxidase and 
trypsin is purchased from MP biomedicals. Synchrotron powder X-ray diffraction 
(PXRD) was carried out on a Bruker D8-Discover diffractometer equipped with a Mo 
sealed tube (λ = 0.72768Å) on the beamline 17-BM at the Advanced Photon Source, 
Argonne National Laboratory. Nuclear magnetic resonance (NMR) data were collected on 
a Mercury 300 spectrometer. Low pressure gas adsorption measurements were performed 
on an ASAP 2020 with the extra-pure quality gases. The UV-Vis absorption spectra were 
recorded on a Shimadzu UV-2450 spectrophotometer. 
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3.2.2 Ligand Synthesis 
Step 1. Synthesis of heptazine-2,5,8-triamine polymer 
 
 
Scheme III-1. Thermo-polymerization of heptazine-2,5,8-triamine. 
 
50 g of melamine was heated at 300oC for 6 h. Then the temperature was raised to 
450oC and kept for another 2 h. The light-yellow solid was washed with 100 mL 10% 
KOH and boiled with concentrated HCl for 10 minutes. The solid was filtered and dried 
in air.  
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Step 2. Synthesis of potassium cyamelurate 
 
 
Scheme III-2. Synthesis of potassium cyamelurate. 
 
25 g poly(heptazine-2,5,8-triamine) was refluxed with 500 mL 2.5 M KOH until 
all the solid were dissolved. Then the solution was concentrated to about 200 mL. The 
solution was cooled in ice bath and the solid was filtered. The filtration was concentrated 
again and another batch of product was collected by filtration. The product was combined 
and dried in air. 
Step 3. Synthesis of heptazine-2,5,8-trichloride 
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Scheme III-3. Synthesis of heptazine-2,5,8-trichloride. 
 
3.87 g potassium cyamelurate and 8.64 g PCl5 was charged in a Schlenk bottle. 
The mixture was heated at 130oC under vacuum overnight. 70 mL POCl3 was added to 
the solid mixture and refluxed for 6 hours. The color of the reaction slurry turned from 
white to yellow. The solvent was removed and the residue solid was washed with minimal 
amount of cold water. The yellow solid was dried in air. 
Step 4. Synthesis of 2,5,8-p-tolyl-s-heptazine 
 
Scheme III-3. Synthesis of 2,5,8-p-tolyl-s-heptazine. 
 
In a 100 mL Schlenk flask was charged 8 g anhydrous AlCl3 and 20 mL anhydrous 
toluene. The mixture was heated to 60 oC under stirring. 3.2 g heptazine-2,5,8-trichloride 
was added to the flask in small portions over 20 minutes. The reaction mixture changed 
from yellow-green to dark red and white gas was generated. The reaction was kept at 60 
oC for 30 minutes and it was cooled down to room temperature. The mixture was poured 
into ice water with rigorous stirring. The resulting yellow solid was filtered and washed 
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with water and cold THF. Yield: 1.5 g. 1H NMR (300 Hz, Benzene), 2.017 (s, 3H), 7.024 
(d, 2H), 8.854 (d, 2H). 
Step 5. Synthesis of HTB ligand 
 
Scheme III-4. Synthesis of HTB ligand. 
 
1 g 2,5,8-p-tolyl-s-heptazine, 20.5 g HOAc, and 1.23 mL H2SO4 was added in a 
100 mL flask in ice bath. 2.03 g CrO3 was added slowly to the flask. Then 1.35 g Ac2O 
was added in. The flask was kept at 0oC for 10 minutes and it was allowed to stay at room 
temperature overnight. The reaction mixture was poured into 300 mL deionized water and 
stirred for 1 hour. The solid was collected by centrifuge and washed with water for three 
times. The product was dissolved with 2.5 M KOH aqueous solution and the residue solid 
was removed by centrifuge. To the clear solution was added 6 M HCl until pH = 1. The 
product was collected by filtration and purified by recrystallization from DMF. Yield: 0.5 
g, yellow solid. 1H NMR (300MHz, DMSO): 8.14 (d, 2H), 8.50 (d, 2H). 
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3.2.3 Synthesis of PCN-888 
AlCl3 6H2O (20 mg), HTB (10 mg) and TFA (0.1 mL) was dissolved in 2 mL DEF 
in a 4 mL Pyrex vial. The mixture was kept in a 135oC oven for 10 hours. The yellow 
solid was collected by centrifuge. Yield: 4 mg. 
3.2.4 Enzyme immobilization of PCN-888 
12 mg glucose oxidase (GOx) was dissolved in 2 mL water. 20 mg horseradish 
peroxidase (HRP) was dissolved in 2 mL water. 4 mg as-synthesized PCN-888 was 
washed with water twice and dispersed in 1 mL water. 1 mL GOx solution was added to 
the MOF slurry and incubated at room temperature for 50 minutes. The solid was 
collected by centrifuge and washed with DI water twice. The MOF was dispersed in 1 mL 
water. 1mL HRP solution was added to the MOF slurry and incubated at room 
temperature for another 50 minutes. The solid was collected by centrifuge and washed 
with water twice. The supernatants were collected for the determination of the amount of 
immobilized enzymes in PCN-888. The uptake amount was determined by the 
bicinchoninic acid (BCA) method.193 
3.2.5 Activation of PCN-888 
Freshly prepared PCN-888 was washed with DMF for three times. The sample was 
evacuated with supercritical CO2 in a Tousimis Samdri PVT-3D critical point dryer. 
Briefly, the DMF-containing sample was placed in the chamber and DMF was completely 
exchanged with liquid CO2. After that the chamber containing the sample and liquid CO2 
was heated up around 40 °C and kept under the supercritical condition (typically 1300 
psi) for 30 minutes. The CO2 was slowly vented from the chamber at around 40 °C, 
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yielding porous material. The yellow solid was further activated by heating at 150°C for 
two hours. 
3.2.6 The measurement of kinetic parameters of PCN-888-en/PCN-888-enR 
ABTS and glucose are dissolved in 1mL 50 mM pH = 7 tris-HCl buffer solution to 
yield desired concentration of ABTS (10 mM) and glucose (0.6-9 mM) solution. MOF 
powder is added in the solution and the system is monitored by UV-vis spectrometer at 
403 nm spontaneously. The measurement is stopped when the adsorption reaches plateau. 
3.2.7 The measurement of kinetic parameters of free enzymes 
The procedure is similar with that of MOF nanoreactors instead of the glucose 
concentration range (1-9 mM), GOx concentration (0.0141 μM,) and HRP concentration 
(0.05057 μM). 
 
3.3 Results and Discussion 
PCN-888 was obtained by a solvothermal reaction with AlCl3 and a heptazine 
based tritopic ligand (HTB) at 135 °C. PCN-888 is isoreticular to PCN-333, which was 
shown earlier by our group.134 High-resolution synchrotron powder X-ray diffraction 
(PXRD) collected at 17-BM, Argonne National Laboratory shows that PCN-888 is cubic 
with an exceptionally large unit cell length a ≈ 143 Å (Figure III-1). PCN-333 crystallizes 
in the space group Fd m, therefore, the same space group was chosen to describe the 
isoreticular PCN-888. The corresponding structural model of PCN-888, with a formula of 
[C54H24N14O16Al3], was simulated based on the reported PCN-333 structure using 
Material Studio 6.0. Rietveld refinement was performed to examine the validity of the 
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structure model, which converged to an acceptable Rwp value of 0.0349, an Rexp of 0.0583 
and an Rp of 0.0181 (Figure III-2). 
The basic secondary building block of PCN-888 is a super tetrahedron, which 
consists of an aluminum trimeric cluster Al3(μ3-O)(OH)(H2O)2 at the four vertices and 
HTB ligand located at the four faces, in a vertex sharing manner. The HTB ligands 
experience geodesic bending to form a domed structure in the framework, giving rise to a 
hierarchical porous structure with three types of mesoporous cages. Besides the super 
tetrahedral cage mentioned above, there are two additional hierarchal mesoporous cages 
in the PCN-888 structure. A smaller dodecahedral cage is composed of 20 super 
tetrahedra connected by vertex sharing with a pentagonal window of 2.5 nm. A larger 
hexacaidecahedral (hexagonal-truncated trapezohedral) cage is surrounded by 28 super 
tetrahedra with not only the 2.5 nm pentagonal windows, but also hexagonal windows of 
3.6 nm. The large cages lie in a honeycomb-like arrangement in the [111] projection. The 
 
 
Figure III-1. Structure and topology of PCN-888. (A) The trimeric cluster and the HTB ligand 
to construct (B) a super tetrahedron; (C) the small cage and (D) large cage of PCN-888 composed 
of the super tetrahedron in a vertex sharing manner; (E) mtn topology with a cell diameter of 14.3 
nm; (F) large cages in a honeycomb-like arrangement viewed from the [111] direction. 
 
 
53 
 
diameter of the inscribed sphere is 2.0 nm for the super tetrahedron cage, 5.0 nm for the 
dodecahedral cage and 6.2 nm for the hexacaidecahedral cage. The porosity of PCN-888 
was determined by Ar adsorption at 87 K and N2 adsorption at 77 K. It has a total Ar 
uptake of 3250 cm3 g 1 and N2 uptake of 2770 cm3 g 1 (Figure III-2). The Brunauer–
Emmett–Teller surface area is over 3700 m2 g 1. The two steep increases at p/p0 = 0.44 
and 0.56 on the adsorption branch of the Ar isotherms correspond to the filling of the 
 
 
 
 
Figure III-2. Structure and porosity analysis of PCN-888. (A) Rietveld refinement patterns of 
PCN-888 using synchrotron PXRD data (λ = 0.72768 Å): observed (blue), calculated (red), and 
difference (grey) profiles are shown; the tick marks below the curves indicate Bragg positions. The 
X-ray diffraction pattern between 1.1° and 4.2° is magnified in the inset. The full pattern shows a 
precise match between the experimental PXRD data and those simulated from the proposed 
structure. (B) Ar isotherms of PCN-888 measured at 87 K. (C) N2 isotherms of PCN-888 
measured at 77 K. Pore size distribution obtained from the N2 isotherm is displayed in the inset. 
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dodecahedral and the hexacaidecahedral cages of PCN-888, respectively. The 
experimental pore volume is 4.0 cm3 g 1. Such a high porosity is among the most porous 
materials reported in the literature and the hierarchical structure indicates that it is 
appropriate for constructing an enzymatic nanoreactor with an ultrahigh enzyme loading 
and low leaching.134, 154, 185, 192  
Only one molecule of GOx (6.0 × 5.2 × 7.7 nm) can fit in the largest cage (6.2 nm) 
of PCN-888, while HRP (4.0 × 4.4 × 6.8 nm) can be accommodated in both the medium 
(5.0 nm) and large cages. Therefore, a stepwise encapsulation with the order → GOx → 
HRP is necessary to precisely control the distribution of GOx and HRP exclusively in the 
largest and medium cages, respectively. With the above order, PCN-888 demonstrated a 
GOx uptake capacity of 1.0 g g 1 and HRP uptake capacity of 2.0 g g 1. The total enzyme 
encapsulation capacity was 300 wt%, which is the highest among all MOFs.132, 134, 138, 188, 
 
 
Figure III-3. Graphic representation of the results of the stepwise encapsulation of GOx and HRP 
with different orders. 
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189, 194 In the following discussion the nanoreactor generated with the →GOx → HRP 
order is named PCN-888-en. 
The porosity of PCN-888-en has dramatically decreased due to the residence of 
enzymes in pores. The total N2 uptake of PCN-888-en was reduced to 400 
cm3 g 1 whereas the BET surface area dropped to 147 m2 g 1. The pore size distribution 
analysis revealed that the pore size of PCN-888-en is predominantly around 1.4 nm, 
which corresponds to the cavity of the smallest pore (super tetrahedron), whereas the 
contributions from the two mesoporous cages of 5.0 nm and 6.2 nm in pristine PCN-888 
disappeared. Consequently, we can conclude that the enzymes are residing in the 
mesoporous cages of PCN-888, while the smallest pore is left empty, which may provide 
a pathway for the diffusion of substrates into the framework. N2 isotherms of GOx@PCN-
888 and HRP@PCN-888 were also collected to prove the size selective incorporation of 
enzymes by different cages. The contribution from the medium cage was present on the 
 
Figure III-4. N2 isotherm of PCN-888-en (A) and the pore size distribution (B) derived from 
N2 isotherm. 
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pore size analysis pattern of GOx@PCN-888 while the mesoporous porosity was fully 
occupied in the case of HRP@PCN-888. 
When the order of enzyme encapsulation was reversed to →HRP → GOx, the 
HRP uptake was higher (2.5 g g 1) whereas the GOx uptake was greatly compromised 
(0.07 g g 1). The reversed order leads to only a surface attachment of GOx, as can be 
revealed from the negligible uptake amount, indicating that bi-enzyme coupling is not 
achieved. The nanoreactor generated with the order →HRP → GOx is named PCN-888-
enR. 
 
 
Table III-1. Kinetic parameters of GOx-HRP in free states, PCN-888-en and PCN-888-
enR in the tandem reaction. 
 Km/mM Vmax/mM · s-1 kcat/s-1 
Free 9.44 1.02 × 10-3 7.253 × 104 
PCN-888-en 9.67 1.96 × 10-3 2.411 × 104 
PCN-888-enR 11.71 1.50 × 10-6 7.946 × 101 
 
 
GOx catalyzes the reaction between glucose and molecular oxygen, generating 
gluconolactone and hydrogen peroxide. Hydrogen peroxide is consumed in the 
conversion of ABTS to ABTS˙+, catalyzed by HRP. The absolute reaction kinetics for this 
tandem reaction was obtained by monitoring the formation of ABTS˙+ at 403 nm by UV-
vis spectroscopy, instead of H2O2, since the rate of reaction catalyzed by GOx is slower 
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than that of HRP.180 The catalytic performance of PCN-888-en was first examined. The 
apparent reaction rate (kcat), substrate affinity (Km) and maximum conversion rate (vmax) of 
PCN-888-en have proved the well maintained catalytic activities of the encapsulated 
enzymes in PCN-888. The design of only one enzyme residing in each pre-designed cage 
effectively prevents enzyme aggregation. Moreover, since large and medium cages are 
stacked in an ABAB layer fashion, the diffusion of substrates and intermediates has a 
very low barrier and short path, which facilitates the conversion of substrates. The 
catalytic performance of PCN-888-enR was also studied. It demonstrated a much worse 
catalytic performance than PCN-888-en, as displayed in Table III-1. This can be 
attributed to the much lower GOx loading in the material and larger diffusion barrier 
between GOx and HRP that are not adjacent to each other. 
 
 
Figure III-5. (A) Leaching test of PCN-888 nanoreactor at 30, 60 and 120 minutes. The 
amount of leaching enzymes were determined by Thermo Scientific PierceTM BCA protein 
assay. The 100% standard solution at 0 minute was composed of 0.14 μM GOx and 1.1 μM 
HRP in water and room temperature. (B) Reusability of PCN-888-en. 
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In comparison with many enzyme loaded silica materials, such as macroporous 
silica foams (MSF), immobilized enzymes always suffer activity loss, due to the partial 
protein unfolding or geometry disruption induced by the strong electrostatic interaction 
between the positively charged protein and negatively charged silica, however, PCN-888 
is electrical neutral so the above mentioned issue no longer exists. For the enzyme loaded 
polymersomes, the encapsulated enzymes inevitably suffer from activity loss since 
organic solvents, such as tetrahydrofuran (THF), are always utilized in the enzyme 
encapsulation procedure. Moreover, the rate of reaction catalyzed by PCN-888-en is 
much faster than that of many polymersomes, in which the conversion of substrates can 
hardly reach a maximum rate within several hours, which is probably attributed to the 
higher enzyme encapsulation capacity of PCN-888 and the empty 2.0 nm cage of PCN-
888 that greatly facilitate diffusion, in contrast to the poorly permeable polymersome 
membranes.179  
The leaching of enzymes from PCN-888 was revealed to be negligible, indicating 
that PCN-888 can provide strong interactions between the cage and the immobilized 
moieties. As a result, the activity of PCN-888-en remained almost the same within four 
catalytic cycles, indicating its promising performance in multiple-cycle uses (Figure III-
6). In a previous report, Ma and coworkers have demonstrated the presence of π π 
interactions between the immobilized enzyme and the conjugated ligands in a mesoporous 
cageMOF.195 The HTB ligand in PCN-888 can form a large conjugated system between 
the heptazine core and terminal benzene rings, which should lead to a strong interaction 
with the immobilized enzymes. At the same time, the small window size of the cages also 
physically prevents the leaching of the enzymes from the framework, although the 
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enzyme has to somehow make its way into the cage, one possible way being unfolding 
and refolding.195 In contrast, enzyme leaching of mesoporous silica materials, such as 
SBA-15, has proved to be significant even after one cycle, resulting in a severe reduction 
of the catalytic activity.134  
The stability of enzymes in a cellular environment is extremely important for the 
widespread biomedical applications of enzymatic nanoreactors.174 Digestion by a 
protease, such as trypsin, is a major deactivation pathway of enzymes in vivo.140 PCN-
888-en has retained almost all of its activity after treatment with trypsin at 37 °C for 60 
minutes, whereas the free enzymes lost two thirds of their activity after the same 
treatment (Figure III-6). The protective effect of PCN-888 can be attributed to the small 
window openings of the enzyme-encapsulated cages, which makes the barrier of the 
immobilized enzymes approaching the active sites of trypsin extremely high. 
 
Figure III-6. Stability of PCN-888 nanoreactor compared with free enzymes incubated in an 
aqueous solution containing 1 mg/mL trypsin at 37 oC for 1 hour. 
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3.4 Conclusion 
In summary, a novel hierarchical MOF, PCN-888, which possesses three types of 
mesoporous cages, is designed and synthesized for bi-enzyme coupling with a precise 
control of the enzyme distribution all over the material. The largest cage and the medium 
cage can only accommodate one molecule of GOx and HRP, respectively, indicating that 
a stepwise encapsulation procedure with a specific order (GOx first, then HRP) is a key 
operation to achieve the coupling. Control experiments demonstrate that bi-enzyme 
coupling failed to be established with a reversed encapsulation order. The high catalytic 
efficiency of the PCN-888 nanoreactor, good cycling performance as well as the 
protective effect of PCN-888 on the immobilized enzymes against trypsin digestion 
indicates that cageMOF tandem nanoreactors have the potential to be applied in more 
complex systems. 
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CHAPTER IV 
HIGH EFFICIENCY AND LONG-TERM INTRACELLULAR ACTIVITY OF AN 
ENZYMATIC NANOFACTORY BASED ON METAL-ORGANIC FRAMEWORKS4 
4.1 Introduction 
The modulation of protein function in live cells is valuable in biotechnology and 
medicine.196 Rescuing enzymatic activity can for instance provide therapeutic benefits for 
the many diseases associated with defective enzymes.197 A general approach used to 
restore protein function involves genetic manipulation, whereby introduction of a gene 
into cells replaces its defective counterpart and insures the production of its protein 
product otherwise lacking. However, genetic manipulations are often problematic as they 
may inadvertently alter the genome of cells and lead to new diseases, including cancer.198-
202 To circumvent this issue, directly using protein supplementation may be preferable. 
However, proteins, in part due to their relative large size and hydrophilicity, do not 
readily penetrate cells. Proteins also have relatively short extra- or intra-cellular half-
lives. If not produced directly inside a cell, proteins may therefore not reach the location 
where their activity is required, and, additionally, not produce a pro-longed effect because 
of their rapid degradation.  
Addressing the problems associated with protein replacement has been the focus of 
intense research. Several techniques have been developed to enhance the cellular delivery 
of these macromolecules, for instance, protein PEGylation or encapsulation in liposomes, 
micelles or polymersomes, to improve transport properties and increase protein half-
4 Reproduced with permission from “High efficiency and long-term intracellular activity of an enzymatic 
nanofactory based on metal-organic frameworks” by Lian, X.; Erazo-Oliveras, A.; Pellois, J.-P.; Zhou, H.-C. Nature 
Commun., 2017, 8, No. 2075, copyright 2017 by Springer Nature. 
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lives.149, 203-212 Another key idea is to increase protein stability by protecting these 
macromolecules from proteolytic degradation using encapsulation agents. In addition, 
encapsulation can help prevent immunological responses that may occur from 
exogenously introduced proteins.204, 205, 213 These strategies have been successful in 
enhancing protein retention time in the circulatory system and in reducing undesired 
accumulation in the liver.213-215 However, other challenges remain. For instance, 
encapsulated enzymes are often quiescent until they are released from their carrier and, 
because release is often inefficient, only a small fraction of the total available enzymatic 
activity is displayed at one time.205 Surface modifications with chemical moieties such as 
PEG can also significantly alter protein structure and reduce activity.216, 217 Overall, 
developing technologies that protect proteins from degradation while maintaining optimal 
protein function is presently highly desirable. 
A possible solution to the problems currently associated with protein formulation 
may lie in the recently developed structures known as metal-organic frameworks (MOFs). 
MOFs are an emerging type of porous materials constructed from metal containing 
clusters and organic linkers. Due to the high porosity as well as structural and functional 
tunability, MOFs hold promises in a variety of applications, including gas 
storage/separation, catalysis, and sensing.39, 47, 153, 218-221 Recently, enzymes have been 
loaded into the cavities of MOFs and immobilized enzymes tested thus far (e.g. 
Horseradish Peroxidase (HRP), Cytochrome C (Cyt c), etc.) have displayed robust in vitro 
activities.132, 188, 222, 223 This indicates that proteins can fold properly in the cavities of 
MOFs and remain functionally active. MOF-immobilized enzymes have also shown 
extraordinary stabilities under denaturing conditions such as extreme heat, high or low 
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pH, and in the presence of organic solvents.224, 225 Moreover, the cage formed by MOFs 
acts as a barrier against proteases, such as trypsin, and protects encapsulated proteins 
from proteolytic degradation.141, 226  
The properties displayed in vitro by MOF-enzyme nanofactories are highly 
attractive. Although the biocompatibility of some MOF materials have been investigated 
in a number of reports, whether MOF-enzyme composites may serve as efficient 
nanofactories in living cells remains untested.223, 227-236 Herein, we aimed to test the 
hypothesis that intracellular MOF nanofactories are capable of supporting an enzymatic 
activity beneficial to living cells for an extended period of time. To test this hypothesis, 
we chose PCN-333(Al) as a MOF platform due to its ultrahigh enzyme encapsulation 
capacity, facile fluorescence modification, and excellent chemical robustness in aqueous 
solutions. As a proof-of-concept study, we established that PCN-333 based nanofactories 
containing the antioxidant enzymes, superoxide dismutase (SOD) and catalase (CAT), 
protect cells from severe oxidative stress, a process involved in a large number of 
pathological states.237-240 Remarkably, this protective effect was maintained for a 
minimum of a week despite the localization of the MOFs inside lysosomes, one of the 
most degradative environments in living cells.241 
 
4.2 Experimental Section 
4.2.1 Materials and Instrumentation 
Aluminum chloride hexahydrate, N-bromosuccinimide (NBS), benzoyl peroxide 
(BPO), ethylenediamine, triethylamine, trifluoroborane etherate, N-hydroxysuccinimide, 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC), N,N-dimethylformamide 
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(DMF), tetrahydrofuran (THF), potassium carbonate, hydrochloric acid and sodium 
hydroxide were purchased from VWR. Carbon tetrachloride, superoxide dismutase 
(SOD), catalase (CAT), SOD assay, horseradish peroxide (HRP) and Amplex Red were 
purchased from Sigma Aldrich. Dulbecco’s minimum essential medium (DMEM), 2-[4-
(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), Leibovitz's L-15 medium 
without cysteine (non-reducing L-15, nrL-15), 10% fetal bovine serum (FBS) and 1× 
penicillin/streptomycin (P/S), Hoechst 33342, Lyso Tracker red, SYTOX Blue and 
SYTOX Green were purchased from Thermo Fisher Scientific. TATB and m-BTB were 
prepared based on the previous report.242 dfTAT used in this paper was resistant to 
peptide hydrolase and was prepared according to previous method.243 pH 5.0 buffer is 50 
mM sodium citrate buffer. pH 7.4 buffer is 50 mM HEPES buffer. 
Synthetic manipulations that required an inert atmosphere (where noted) were 
carried out under nitrogen using standard Schlenk techniques. Powder X-ray diffraction 
(PXRD) was carried out on a Bruker D8-Focus Bragg-Brentano X-ray powder 
Diffractometer equipped with a Cu sealed tube (λ = 1.54178) at 40 kV and 40 mA. N2 
sorption isotherms at 77 K were measured by using a Micrometritics ASAP 2420 system 
with high-purity grade (99.999%) of gases. UV-Vis spectra were recorded on Shimadzu 
UV-2450 spectrophotometer. Fluorescence spectra were recorded on a Hitachi F-4600 
spectrometer (Hitachi Co. Ltd., Japan) with Xe lamp as the excitation source at room 
temperature. ICP analysis was conducted on PerkinElmer NexION 300D instrument. 
Dynamic light scattering and Zeta potential were measured at 25 °C on a Zetasizer Nano 
ZS ZEN3600 analyser (Malvern Instrument Ltd, UK). Confocal laser scanning 
microscopy (CLSM) imaging was performed on an inverted epifluorescence microscope 
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(Model IX81, Olympus) was equipped with a heating stage maintained at 37 °C. Images 
were collected using a Rolera-MGI Plus back-illuminated electron-multiplying charge 
coupled device (EMCCD) camera (Qimaging). Images were acquired using bright-field 
imaging and three standard fluorescence filter sets: DAPI (excitation (Ex) = 350 ± 10 
nm/emission (Em) = 440 ± 20 nm), RFP (Ex = 560 ± 20 nm/Em = 630 ± 35 nm) and 
FITC (Ex = 488 ± 10 nm/Em = 520 ± 20 nm). The images were processed with the 
SlideBook 4.2 software (Olympus) and ImageJ2. Inductively coupled plasma mass 
spectrometry (ICP-MS) was carried out on an Agilent 7700x series ICP-MS instrument. 
TEM images were taken on a transmission electron microscopy (JEOL JEM-2100F, 
Japan) operated at an acceleration voltage of 200 keV by dropping solution onto a carbon-
coated copper grid. 
HeLa (ATCC CCL-2), NIH3T3 (ATCC CRL-1658) and HDF (ATCC PCS-201-
012) were grown in DMEM supplemented with FBS and P/S and kept at 37 °C in a 
humidified atmosphere containing 5% CO2. Cell experiments are performed in 
quintuplicates for each condition and are repeated with three different batches of cells. 
Statistic tests are studied by multiple t tests method. HeLa cells are common vitro model 
for oxidative stress studies.244-246 
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4.2.2 Synthesis of BTB-Green 
Step 1. Synthesis of dimethyl 2'-(bromomethyl)-5'-(4-(methoxycarbonyl)phenyl)-
[1,1':3',1''-terphenyl]-4,4''-dicarboxylate (compound 1) 
 
 
3.68 g m-BTB, 1.35 g NBS and 50 mg BPO was dispersed in 45 mL CCl4 and 
refluxed at 80oC for 12 h. The precipitate was filtered and the filtrate was dried under 
vacuum. Compound 1 was obtained as light yellow solid. Yield: 100%. 
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Step 2. Synthesis of dimethyl 2'-(((2-aminoethyl)amino)methyl)-5'-(4-
(methoxycarbonyl)phenyl)-[1,1':3',1''-terphenyl]-4,4''-dicarboxylate (Compound 2) 
 
 
 
1.6 g compound 1 was dissolved in 60 mL THF. 1 mL ethylenediamine was added 
and the mixture was stirred under room temperature for 6 h. Saturated NaHCO3 solution 
was added and the aqueous phase was extracted with CH2Cl2 for 3 times. The combined 
organic phase was dried over MgSO4 and the solvent was removed under vacuum. 
Compound 2 was obtained as light yellow solid. 
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Step 3. Synthesis of 2'-(((2-aminoethyl)amino)methyl)-5'-(4-carboxyphenyl)-
[1,1':3',1''-terphenyl]-4,4''-dicarboxylic acid (Compound 3) 
 
 
 
1.8 g compound 2 was dissolved in THF and 20 mL 2 M NaOH solution was 
added. The mixture was refluxed for 6 h after which THF was removed under vacuum. 6 
M HCl was added until compound 3 precipitated as white solid, which was filtered and 
dried under vacuum. 
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Step 4. Synthesis of methyl 2-(4-(4,4-difluoro-1,3,5,7-tetramethyl-3a,4-dihydro-4l4-
dicyclopenta[b,e]borinin-8-yl)phenoxy)acetate (Compound 2’) 
 
 
0.95 g 2, 4-dimethylpyrrole and 1.04 g compound 1’ was dissolved in 150 mL 
THF. 3 drops of TFA was added and the mixture was stirred overnight at room 
temperature under darkness, after which 2 g DDQ dissolved in 50 mL THF was added 
and stirred for 30 minutes. 25 mL triethylamine was added to the mixture, and 31 mL 
BF3·Et2O was added over 30 minutes. The mixture was stirred for 6 h and compound 2’ 
was obtained by column chromatography (CH2Cl2: hexanes = 1: 2) as an orange solid. 
Yield: 50%. 
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Step 5. Synthesis of 2-(4-(4,4-difluoro-1,3,5,7-tetramethyl-3a,4-dihydro-4l4-
dicyclopenta[b,e]borinin-8-yl)phenoxy)acetic acid (Compound 3’) 
 
 
0.4 g compound 2’ and 0.8 g K2CO3 was dissolved in a 1:1 mixture of THF and 
water. The solution was heated at 50oC for 24 h, after which the solvent was removed 
under vacuum. Water was added to the solid and abstracted by CH2Cl2 for 3 times in 
order to remove the unreacted compound 2’. The aqueous phase was added 1 M HCl until 
pH reached 7. Compound 3’ was obtained by filtration and vacuum drying as an orange 
solid. Yield: 99%. 
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Step 5. Synthesis of 2,5-dioxocyclopentyl 2-(4-(4,4-difluoro-1,3,5,7-tetramethyl-3a,4-
dihydro-4l4-dicyclopenta[b,e]borinin-8-yl)phenoxy)acetate (Compound 4’) 
 
 
 
350 mg compound 3’, 200 mg N-hydroxysuccinimide and 340 mg EDC was 
suspended in 20 mL CH2Cl2 under N2 atmosphere. The mixture was stirred at room 
temperature for 12 h and diluted by 200 mL 1:1 CH2Cl2/H2O. The organic phase was 
dried and compound 4’ was obtained as an orange solid. Yield: 100%. 
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Step 6. Synthesis of 5'-(4-carboxyphenyl)-2'-(((2-(2-(4-(4,4-difluoro-1,3,5,7-
tetramethyl-3a,4-dihydro-4l4-dicyclopenta[b,e]borinin-8-
yl)phenoxy)acetamido)ethyl)amino)methyl)-[1,1':3',1''-terphenyl]-4,4''-dicarboxylic 
acid (BTB-Green) 
 
 
510 mg compound 3 and 495 mg compound 4’ was dissolved in 20 mL DMF and 
1mL triethylamine was added. The mixture was stirred at room temperature for 12 h and 
diluted with 100 mL water. 1 M HCl was added until pH reached 4. BTB-Green was 
obtained by filtration and vacuum drying as an orange solid. Yield: 100%. ESI+: 
891.3371. 
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4.2.3 Synthesis of NPCN-333 
10 mL DMF solution of AlCl3· 6H2O (1.5 mg/mL), 5 mL DMF solution of TATB 
(1 mg/mL), 15 mL DMF and 50 μL TFA was mixed and heated at 95oC for 24 h. NPCN-
333 was collected by centrifugation. 
4.2.4 Synthesis of FNPCN-333 
30 mg NPCN-333 was dispersed in 5 mL DMF in which was added 5 mL 10 
mg/mL DMF solution of BTB-Green. The mixture was kept in 85oC oven for 4 h and the 
solid was collected by centrifugation. The determination of the amount of metathesized 
ligand was conducted by digesting the obtained solid in HCl, dried under vacuum and 
dissolved in deuterated DMSO for NMR analysis. The ligand ratio of BTB-Green/TATB 
is 1:6. 
4.2.5 Stepwise encapsulation of SOD and CAT on FNPCN-333 
Stock solutions of SOD (5 mg/mL) and CAT (5 mg/mL) were prepared by 
dissolving SOD and CAT in deionized water, respectively. 1 mg FNPCN-333 was 
suspended in water in which 1 mL CAT stock solution was added. The mixture was 
vortexed for 20 minutes and the solid was collected by centrifugation and washed by 
fresh water for 3 times. The solid was re-suspended in 1 mL water and 1 mL SOD stock 
solution was added. The mixture was kept vortexing for 20 minutes and the solid was 
collected by centrifugation. SC@FNPCN-333 was washed with fresh water for 3 times 
before re-suspended in 0.3 mL water. 
4.2.6 WST assay for determining SOD activity 
WST assay kit is purchased from Sigma Aldrich. 20 µL sample solution containing 
different concentrations of SC@FNPCN-333 is mixed with 200 µL working solution. 
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Then 20 µL WST solution (1mL WST stock solution diluted by 19 mL working solution) 
is added and well mixed. Finally, 20 µL xanthine oxidase (XOD) solution (15 µL XOD 
stock solution diluted with 2.5 mL working solution) is added and the solution is 
incubated at 37oC for 30 minutes. The reading at 450 nm is collected by UV-vis 
spectroscopy. 
4.2.7 Amplex Red-HRP assay for determining CAT activity 
20 µL sample solution containing different concentrations of SC@FNPCN-333 is 
mixed with 200 µL hydrogen peroxide PBS solution (final concentration is 40 µM) and 
incubates at 37oC for 30 minutes. Then 20 µL HRP solution (0.4 U/mL) and 20 µL 
Amplex Red solution (100 µM) is added and incubates at 37oC for another 30 minutes. 
Fluorescence is collected with excitation wavelength of 540 nm and emission wavelength 
of 590 nm. 
4.2.8 Cell internalization of SC@FNPCN-333 and CLSM imaging 
HeLa cells were seeded in an 8 well plate and allowed to adhere overnight. Then 
the culture media was replaced by 200 µL fresh nrL-15 media containing SC@FNPCN-
333 with different concentrations at 37oC for 15-480 minutes in darkness. The cells used 
for CLSM imaging was cultured in 75 µg/mL SC@FNPCN-333 for 2 h. Representatively, 
for the CLSM imaging, media containing SC@FNPCN-333 was removed and cells were 
washed with fresh nrL-15 for 3 times before they were stained with Hoechst 33342 (5 
µg/mL), Lyso Tracker red (10 µg/mL) and SYTOX Blue (5 µg/mL). The cells were then 
incubated for 5 minutes before they were imaged. Co-incubation of SC@FNPCN-333 and 
D-dfTAT (20 µM) was conducted in the same manner. The only difference lied in the cell 
staining step. The cells were only stained with SYTOX Blue. 
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4.2.9 Cell lysis protocol 
Cells are cultured in a 48 well plate and treated before the culture medium is 
removed. Cells are washed with fresh PBS for three times and five representative images 
are obtained by a confocal microscopy to count the cell number in the plate. Then the 
cells are digested by 200 µL concentrated nitric acid overnight. Each sample is measured 
three times by ICP-MS. 
4.2.10 Intracellular Al content measurement at day 7 
Cells (80-90% confluency) is cultured with 75 µg/mL SC@FNPCN-333 in nrL-15 
for 2 h. Then the cells are washed with frest nrL-15 for three times and cultured with 
fresh DMEM. Cells are trypsinized and re-plated at day 1, 3, and 5. At day 7 the culture 
medium is removed and the cells are treatment with concentrated nitric acid overnight. 
The sample is measured three times by ICP-MS. Original Al content value: 104.1 ± 2.8 
ng Al/105 cells, mean ± s.d. 
4.2.11 In cellulo antioxidative activity evaluation of SC@FNPCN-333 
HeLa cells were seeded in a 48 well plate and allowed to adhere overnight. For the 
positive control groups, cell culture media was replaced by 200 µL fresh DMEM media 
containing PQ with concentrations from 0.5 mM to 10 mM. The cells were cultured at 
37oC for 24 h, then the cells were washed with fresh PBS buffer for 3 times before 
charged with fresh nrL-15 buffer. The cells were stained with Hoechst 33342 (5 µg/mL) 
and SYTOX Green (5 µg/mL). To evaluate the antioxidative activity of SC@FNPCN-
333, cells were treated with 75 µg/mL SC@FNPCN-333 for 2 h before charged with PQ 
solutions for 24 h. The washing and staining operations were the same as positive 
controls. Hoechst 33342 was excited for 500 ms and SYTOX Green was excited for 300 
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ms. 5 images were taken in each well. Each treatment condition was replicated for 3 
wells. 
4.2.12 Real-time ROS monitoring in living cells 
Cells are cultured in a 48 well plate and are treated with SC@FNPCN-333 for 2 h 
in nrL-15. Then the medium is removed and the cells are washed with fresh nrL-15 for 
three times. Then the cells are incubated with nrL-15 containing 500 µM pyocianin and 5 
µM superoxide detection dye for 30 minutes before imaged by a confocal microscope.  
4.2.13 Theoretical estimation of enzyme loading in NPCN-333 
In each unit cell of PCN-333, there are eight of A-cages (5.5 nm) and 16 of B-
cages (4.2 nm). The volume of each unit cell = (126 Å)3 = 2.0 × 10-18 cm3. The density of 
PCN-333(Al) = 0.23 g/cm3. So the mass of each unit cell = ρ × V = 0.46 × 10-18 g. 
Therefore, the total number of unit cells per gram of PCN-333(Al) is: 1/(0.46 х 10-18) = 
2.2 х 1018. And the A-cage in each gram of PCN-333(Al) = 2.2 × 1018 × 8 = 1.7 × 1019 = 
2.9 × 10-5 mol. B-cage in each gram of PCN-333(Al) = 3.4 × 1019 = 5.8 × 10-5 mol. For 
SOD, MW = 16.3 kDa, so the maximum loading is 16300 × 5.8 × 10-5 = 0.92 g/g. For 
CAT, MW = 64 kDa, so the maximum loading is 60000 × 2.9 × 10-5 = 1.74 g/g. 
4.2.14 Theoretical estimation of enzyme loading in FNPCN-333 
In each unit cell of PCN-333, there are eight of A-cages (5.5 nm) and 16 of B-
cages (4.2 nm). The volume of each unit cell = (126 Å)3 = 2.0 × 10-18 cm3. The density of 
FNPCN-333(Al) = 0.26 g/cm3. So the mass of each unit cell = ρ × V = 0.52 × 10-18 g. 
Therefore, the total number of unit cells per gram of PCN-333(Al) is: 1/(0.52 х 10-18) = 
1.95 х 1018. And the A-cage in each gram of PCN-333(Al) = 1.95 × 1018 × 8 = 1.5 × 1019 
= 2.6 × 10-5 mol. B-cage in each gram of PCN-333(Al) = 3.0 × 1019 = 5.2 × 10-5 mol. For 
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SOD, MW = 16.3 kDa, so the maximum loading is 16300 × 5.2 × 10-5 = 0.82 g/g. For 
CAT, MW = 64 kDa, so the maximum loading is 60000 × 2.6 × 10-5 = 1.56 g/g. 
4.2.15 Colocalization coefficient estimation 
For cellular colocalization experiments, the Manders’ overlap coefficient R 
(measures how interdependent the red and green channels are) and colocalization 
coefficient M1 (measures the percentage of above-background pixels in the red channel 
that overlap with the above-background pixels in the green channel) were calculated 
using ImageJ (NIH).  
 
4.3 Results  
4.3.1 Preparation and characterization of PCN-333 nanoparticles 
The basic secondary building unit of PCN-333 is a supertetrahedron, which 
consists of an aluminum trimeric cluster at the four vertices and TATB ligands on the 
faces, in a vertex sharing manner (Figure IV-1). The supertetrahedron is the secondary 
building block for two mesoporous cavities: a smaller dodecahedral cage composed of 20 
supertetrahedra connected by vertex sharing with exclusive pentagonal windows and a 
larger hexacaidecahedral (hexagonal-truncated trapezohedral) cage surrounded by 28 
supertetrahedra with both pentagonal and hexagonal windows. The cavity size of 
supertetrahedral, dodecahedral and hexacaidecahedral cage is 1.1, 4.2 and 5.5 nm. 
Nanoscale PCN-333 (NPCN-333) was synthesized in the condition similar to that of 
microscale PCN-333, with differences lying in the concentration of starting material and 
the amount of modulating reagents. Transmission electron microscopy (TEM) images 
indicated that NPCN-333 particles possessed spherical shape with an average diameter of 
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100 nm (Figure IV-1). This diameter was coincident with that measured by dynamic light 
scattering (DLS). The as-synthesized particles demonstrated high crystallinity as 
determined by powder X-ray diffraction (PXRD). The pattern was isostructural to PCN-
333, although the peaks were broadened due to the reduced particle size. N2 isotherm at 
77K revealed that the NPCN-333 was highly porous with hierarchical porosity. The 
surface area was 2793 m2 g-1 and the void volume was 2.94 cm3 g-1. FNPCN-333, a 
 
 
Figure IV-1. Structure and characterization of PCN-333 nanoparticles. (a) PCN-333 is 
composed of trimeric clusters and TATB ligands, which self-assemble into supertetrahedra 
(highlighted in red dashed circle). The supertetrahedra are connected with each other in a 
vertex-sharing manner. A green fluorophore is anchored on NPCN-333 via ligand metathesis. 
(b) TEM image of NPCN-333. Scale bar: 100 nm. (c) TEM image of FNPCN-333. Scale bar: 
100 nm. (d) Powder X-ray diffraction patterns (2θ from 2 to 15 degree) of microscale PCN-
333 (black); NPCN-333 (red); FNPCN-333 (green); SC@FNPCN-333 (blue); NPCN-333 
soaked in DMEM for 1 day (cyan); NPCN-333 soaked in DMEM for 7 days (magenta). 
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fluorescent version of NPCN-333 prepared for live cell fluorescence microscopy 
experiments, was prepared via ligand metathesis of NPCN-333 with a BTB ligand 
functionalized with the fluorophore BODIPY. FNPCN-333 displays particle size, 
distribution, and porosity properties similar to those of NPCN-333 (surface area 2428 m2 
g-1, void volume 2.30 cm3 g-1) (Figure IV-2). The presence of BTB-Green on the 
framework backbone is also confirmed by the relatively larger distribution of 
microporosity in FNPCN-333 than that of NPCN-333. However, unlike NPCN-333, 
FNPCN-333 is fluorescent with a maximal emission at 509 nm in water. As previously 
reported, PCN-333 is stable in aqueous solutions over a pH range of 3 to 9. When particle 
size decreased, the chemical stability was not compromised. The well-maintained 
 
 
Figure IV-2. TEM images of SC@FNPCN-333 (a) and NPCN-333 after soaking in DMEM 
for 7 days (b). The zoomed in images show the fringes on the crystals. Scale bar: 100 nm (a), 
200 nm (b), 50 nm (c-e). 
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crystallinity of FNPCN-333 was confirmed by the unchanged PXRD pattern as well as 
the fringes on the crystals after soaking in the cell culture media for up to 7 days. 
4.3.2 Enzyme encapsulation and protection by FNPCN-333 
An early examination of the molecular dimensions of SOD (2.8*3.5*4.2 nm3, 16.3 
kDa)247 and CAT (4.9*4.4*5.6 nm3, 60 kDa)248 indicated that these proteins could 
potentially fit in the 4.0 and 5.5 nm cavities of FNPCN-333, respectively. To test this 
idea, the two enzymes were incorporated into FNPCN-333 in a stepwise manner.141 First, 
 
Figure IV-3. Enzyme encapsulation on FNPCN-333. (a) Schematic representation 
illustrating the relative size of the cavities present in FNPCN-333 and of the enzymes SOD 
and CAT (from PDB 1CBJ and 5GKN). The medium (grey) and large (orange) cavities of 
FNPCN-333 accommodate SOD (green) and CAT (cyan), respectively. (b)(c) N2 isotherms 
of FNPCN-333 (b) and SC@FNPCN-333 (c) at 77K. Inlets show pore size distribution 
diagram derived from N2 isotherm.  
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FNPCN-333 was incubated with CAT so as to occupy the larger MOF cavities. After 
addition of CAT, FNPCN-333 was incubated with SOD to load the smaller cavities that 
would not accommodate CAT. Based on BCA analysis, the encapsulation capacity of 
FNPCN-333 for SOD and CAT was 0.80 and 1.26 g g-1, respectively. This is comparable 
to the calculated values of maximal encapsulation capacity (0.92 and 1.74 g g-1) and is 
indicative of a high loading efficiency. Consistent with this notion, N2 isotherm analysis 
shows that enzyme encapsulation leads to complete disappearance of the two mesoporous 
cavities. In contrast, the microporous cavities that are too small in volume to 
accommodate the protein molecules remain detectable. The crystallinity of the resulting 
bi-enzymatic nanofactory, named SC@FNPCN-333, was well maintained, as indicated by 
PXRD patterns. Thermal gravimetric analysis (TGA) further confirms high enzyme 
loading of FNPCN-333. 
In order to determine whether encapsulated SOD and CAT are biologically 
functional, the water-soluble tetrazolium (WST) and horseradish peroxidase (HRP)-
Amplex Red assays were performed. In the WST assay, the activity of SOD is detected by 
spectroscopically measuring the superoxide-mediated reduction of WST (pale yellow) to 
the formazan dye (dark yellow). In the HRP-Amplex Red assay, the fluorescent dye 
resorufin is produced upon oxidation of Amplex Red with hydrogen peroxide, a reaction 
catalyzed by HRP. By catalyzing the decomposition of hydrogen hydroxide, CAT inhibits 
the generation of resorufin. As shown in Fig. 2b, the superoxide detoxifying activity of 
SC@FNPCN-333 was comparable to that of free SOD. Similarly, the peroxide 
scavenging activity of SC@FNPCN-333 was comparable to that of free CAT (Figure IV-
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4). Notably, SC@FNPCN-333 displayed persistent CAT and SOD enzymatic activities 
after soaking in the cell culture media (DMEM) for 7 days. 
Resistance of the enzymatic nanofactory towards cellular degradation, from factors 
such as proteases and acidic pH, is crucial for its long-term performance in living cells. 
 
 
Figure IV-4. In vitro determination of enzymatic activities and resistance to perturbations. (a) 
SDS-PAGE analysis of SC@FNPCN-33 after exposure to the protease trypsin. L: protein 
ladder. Lane 1: free SOD (highlighted with black arrow) and CAT (highlighted with red arrow). 
Lane 2: Free SOD and CAT after treatment with trypsin for 1 h. Lane 3: SC@FNPCN-333 
treated with trypsin for 1 h (analyzed after dissolution of MOF in HCl). (b) Relative enzymatic 
activities of several SOD formulations, as determined by the superoxide inhibition assay: free 
SOD (blue), freshly prepared SC@FNPCN-333 (orange), SC@FNPCN-333 stored for 7 days 
(green), SC@FNPCN-333 treated with trypsin for 2 h (black). n = 3, mean ± s.d. (c) Relative 
enzymatic activities of several CAT formulations, as measured by the inhibition of H2O2-
mediated production of the fluorophore resorufin: free CAT (blue), freshly prepared 
SC@FNPCN-333 (orange), SC@FNPCN-333 stored for 7 days (green), SC@FNPCN-333 
treated with trypsin for 2 h (black). n = 3, mean ± s.d. (d)(e) Relative SOD (d) and CAT (e) 
activities of free enzyme and SC@FNPCN-333 after soaking in pH 5.0 buffer for 24 h. n = 3, 
mean ± s.d. 
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To test whether NPCN-333 could provide a protective environment for SOD and CAT, 
SC@FNPCN-333 was first exposed in vitro for 2 h to the protease trypsin. SC@FNPCN-
333 was subsequently treated with HCl so as to dissolve the MOF and release 
encapsulated proteins, including potential trypsin-digested enzyme fragments. The 
resulting supernatants were analyzed by SDS-PAGE. Trypsin readily digests SOD and 
CAT in their free form, as illustrated by the presence of small molecular weight bands 
(Figure IV-4). In contrast, bands corresponding to intact SOD and CAT are 
predominantly present for SC@FNPCN-333. In addition, SC@FNPCN-333 maintained 
its enzymatic activities after trypsin treatment, as indicated by the WST and HRP-Amplex 
Red assays. In order to test whether the nanofactories resist exposure to an acidic milieu, 
SOD, CAT and SC@FNPCN-333 were incubated at pH 5 (this pH mimics the luminal pH 
of late endosomes and lysosomes, organelles inside which MOF can accumulate, as 
shown below). Enzymatic activities were measured at 0.5 and 24 h and compared to those 
obtained at pH 7.4. After 0.5 h incubation, the acidic pH led to a moderate loss in activity 
for the free enzymes and for SC@FNPCN-333 (approximately 15 to 25% for 
SC@FNPCN-33 and CAT, 35% for SOD). After 24 h incubation, the activities of SOD 
and CAT at pH 5 were reduced to only 10 or 20% of those obtained at pH 7.4, 
presumably because of slow unfolding of the proteins. In contrast, the activities of 
SC@FNPCN-333 at pH 5 were unchanged during the course of the experiment (>80% 
relative activity at 1 and 24 h). Together, these experiments indicate that FNPCN-333 
provides a platform for high enzymatic activity, protection from proteases, and resistance 
under a broad pH range. These encouraging data also set the stage for in cellulo testing.  
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4.3.4 Cellular uptake of SC@FNPCN-333 
In order to exert optimal enzymatic activities, exogenously administered enzyme 
nanofactories should ideally reach the intracellular locations occupied by their 
endogenous counterparts. SOD is localized in the cytosolic space and mitochondria of 
 
Figure IV-5. Cellular internalization of SC@FNPCN-333 by HeLa cells. (a) 100X 
microscopy images of SC@FNPCN-333 (75 µg mL-1) incubated with HeLa cells for 2 h, then 
stained with the nuclear marker Hoechst 33342 and LysoTracker red. Cell nuclei, 
SC@FNPCN-333 and LysoTracker red labeled acidic organelles (i.e. late endosomes and 
lysosomes) are pseudo-colored in cyan, green and red, respectively. The arrow in the 
enlarged green/red overlay image illustrates the colocalization of puncta containing both 
SC@FNPCN-333 and LysoTracker red. Pearson’s correlation coefficient R and Mander’s 
correlation coefficient M1 is indicated. Scale bar: 10 µm. (b) 100X microscopy images of 
SC@FNPCN-333 co-incubated with the cytosolic delivery agent dfTAT for 2 h. The image is 
an overlay of SC@FNPCN-333 (pseudocolored green) and dfTAT (pseudocolored red). The 
arrow points to a dfTAT-stained nucleolus, indicative of effective cytosolic penetration of the 
delivery reagent. The enlarged image illustrates the green fluorescence of SC@FNPCN-333 
in the cytosolic space and, by contrast, a dark area suggestive of the exclusion of 
SC@FNPCN-333 from the cell nucleus. Scale bar: 10 µm. (c) ICP-MS analysis of Al content 
in HeLa cells incubated with SC@FNPCN-333 (75 µg mL-1) for varying time points. n = 3, 
mean ± s.d. (d) ICP-MS analysis of Al content in HeLa cells incubated with varying 
concentrations of SC@FNPCN-333 for 2 h. n = 3, mean ± s.d. 
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human cells while CAT is typically localized in peroxisomes.249, 250 On one hand, given 
the size and biophysical properties of MOF, we did not anticipate that SC@FNPCN-333 
would spontaneously penetrate into the cytosolic space of cells and reach these 
intracellular destinations. On the other hand, 100 nm particles are small enough to allow 
for cellular uptake by endocytosis. We therefore envisioned that endosomal entrapment of 
SC@FNPCN-333 should be possible. Furthermore, we have recently developed dfTAT, a 
delivery reagent that causes leakage of late endosomes and permits the release of 
endocytosed cargos into the cytosolic space of cells.243, 251, 252 To test whether 
SC@FNPCN-333 endosomal or cytosolic localization could be achieved, SC@FNPCN-
333 was incubated with HeLa cells for 2 h, with or without dfTAT. When administered 
alone to live cells, SC@FNPCN-333 displayed an intracellular punctate fluorescence 
distribution, as observed by microscopy. Colocalization of SC@FNPCN-333 with 
LysoTracker red, a late endosome and lysosome marker,253 confirmed entrapment of the 
enzyme nanofactories within these endocytic organelles (L.E./LYS, Figure IV-5). 
Consistent with these results, incubation of SC@FNPCN-333 with HeLa cells at 4 oC, a 
condition that inhibits energy-dependent endocytic uptake, or in the presence of 
amiloride, an inhibitor of macropinocytosis, led to a dramatic reduction in the number of 
intracellular SC@FNPCN-333-positive puncta and to a reduction of co-localization with 
LysoTracker red. When administered in the presence of dfTAT, SC@FNPCN-333 
presented a homogeneously diffuse fluorescence distribution, indicative of localization in 
the cytosolic area, albeit was accompanied by a residual punctate distribution indicative 
of incomplete endosomal escape. Moreover, consistent with the notion that the size of 
SC@FNPCN-333 exceeds the nuclear pore complex size threshold for passive diffusion, 
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the cytosolic green fluorescence distribution of SC@FNPCN-333 was excluded from 
 
Figure IV-6. Effect of low temperature (4 oC) and endocytosis inhibitor (amiloride) on the 
cellular internalization of SC@FNPCN-333 by HeLa cells. Zoom-in images are provided. 4 
oC colocalization coefficient: 0.34 (Pearson’s), 0.30 (Mander’s). 37oC with amiloride 
colocalization coefficient: 0.61 (Pearson’s), 0.58 (Mander’s). Scale bar: 10 µm. 
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nuclei (Figure IV-5). By extension, this staining supports the notion that the diffuse 
fluorescence observed from SC@FNPCN-333 is indeed cytosolic (in other words, 
artifactual out-of-focus extracellular signals would not be selectively excluded from 
nuclei). Overall, these results indicate that the intracellular accumulation of enzymes 
nanofactories can be achieved and that their intracellular distribution can be modulated. 
Notably, the cytotoxicity of SC@FNPCN-333, evaluated using a SYTOX Blue exclusion 
assay, was negligible, in the presence and absence of dfTAT. In particular, cell viability 
was more than 97% at 0 or 24 h post-incubation, a result identical to that obtained with 
untreated cells. 
In order to optimize MOF cellular uptake and given that the two cellular delivery 
approaches used above are dependent on endocytosis, we next tested the dependence of 
MOF endocytic uptake on time and concentration. To quantify the endocytic uptake of 
SC@FNPCN-333, the aluminum (Al) content of cells incubated with SC@FNPCN-333 
was measured by ICP-MS. For instance, cells were incubated with 75 µg mL-1 
SC@FNPCN-333, harvested at different time points, and lysates were prepared for 
analysis. As shown in Figure IV-5, Al levels dramatically increased after 30 minutes 
incubation and, after 2 h incubation, reached a plateau corresponding to 89.2 ± 3.7 nmol 
nanoparticle per 105 cells. Alternatively, cells were incubated with varying amounts of 
SC@FNPCN-333 and analyzed after 2 h incubation. In this case, internalization initially 
increased with SC@FNPCN-333 concentration but reached a plateau at 75 μg mL-1. 
Together, these results indicate that incubation of cells with 75 μg mL-1 SC@FNPCN-333 
for 2 h leads to maximal cellular uptake. We therefore chose these conditions for 
subsequent studies.  
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4.3.5 In cellulo activity of SC@FNPCN-333 
To address whether SC@FNPCN-333 can protect cells from ROS-induced 
toxicity, we established an assay in which cells are exposed to oxidative stress. In 
particular, we treated cells with paraquat (PQ), a redox-active herbicide previously linked 
to various human diseases, including organ failure and Parkinson’s disease.254 As 
expected, cells treated with varying concentrations of PQ (0.5-10 mM) for 24 hours 
showed reduced cell viability when compared to untreated cells (Figure IV-7). Pretreating 
cells with FNPCN-333 (75 μg mL-1, 2h) did neither increase nor decrease cell viability, 
indicating that MOF alone do not interfere with the toxicity of PQ. In contrast, when cells 
were pre-treated with SC@FNPCN-333 (75 μg mL-1, 2h; this condition leads to L.E./LYS 
 
 
Figure IV-7. Protection of HeLa cells from oxidative stress by SC@FNPCN-333. (a) 
Viability of cells treated with the oxidant paraquat (PQ) for 24 h. Blue: control. Green: cells 
pre-treated with FNPCN-333. Orange: cells pre-treated with SC@FNPCN-333 (75 µg mL-1) 
for 2 h. Magenta: cells pre-treated with SOD (60 µg mL-1) and CAT (94.5 µg mL-1) for 2 h. n 
= 5, mean ± s.d. *** represents P≤0.001. (b) CLSM images of HeLa cells as control, treated 
with 10 mM PQ for 24 h, pre-treated with SC@FNPCN-333 then treated with 10 mM PQ for 
24 h. Left panel: bright field images; middle panel: cell nucleus stained with Hoechst 33342; 
right panel: dead cell nucleus stained with SYTOX Green. Scale bar: 100 µm. 
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accumulation), cell viability was restored to a high degree, with more than 85% of cells 
surviving the most cytotoxic PQ treatment. In comparison, pretreating cells with either 
free enzymes, or with MOF loaded with only SOD or CAT (S@FNPCN-333 or 
C@FNPCN-333) led to only a minor improvement in cell viability. Moreover, a mixture 
of S@FNPCN-333 and C@FNPCN-333 did not perform as well as SC@FNPCN-333, 
 
Figure IV-8. Protection of HeLa cells from oxidative stress by SC@FNPCN-333. (a) 
Viability of cells treated with PQ (10 mM) for 24 h following pre-treatments with various 
enzyme formulations. Purple: control of cells with no pretreatment. Green: cells pre-treated 
with SOD (60 µg mL-1) and CAT (94.5 µg mL-1) for 2 h. Orange: cells pre-treated with 
S@FNPCN-333 (75 µg mL-1) for 2 h. Blue: cells pre-treated with C@FNPCN-333 (75 µg 
mL-1) for 2 h. Light grey: cells pre-treated with S@FNPCN-333 (75 µg mL-1) and 
C@FNPCN-333 (75 µg mL-1) for 2 h. Red: cells pre-treated with SC@FNPCN-333 (75 µg 
mL-1) for 2 h. n = 5, mean ± s.d. * and *** represent P<0.05 and P≤0.001, respectively. (b) In 
cellulo ROS detoxification by SC@FNPCN-333. Presence of superoxide, which generates an 
oxidized and red fluorescent form of SDR, was detected by fluorescence microscopy. 
Fluorescence microscopy images (20X magnification) of SDR are pseudocolored red. Images 
were acquired and processed using identical conditions. Intensity bars show the relative 
fluorescence intensities of the 3 images (normalized to a highest signal of 100). The 
experiment was replicated for three times and representative images are displayed. Scale bar: 
10 µm. 
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pointing to a beneficial effect of enzyme proximity obtained from co-encapsulation. In 
order to validate that SC@FNPCN-333 exerts a protective effect by mediating ROS 
detoxification, the impact of the enzymes nanofactory on ROS levels was assessed by 
microscopy. Cells were incubated with pyocyanin, a bacterial toxin that produces 
superoxide, and a fluorescent Superoxide Detection Reagent (SDR). Microscopy imaging 
shows that, the fluorescence of SDR, which is proportional to the superoxide 
concentration in cells, increased in the presence of pyocyanin. However, upon 
pretreatment with SC@FNPCN-333, the SDR signal was restored to basal level (Figure 
IV-8). When the cellular uptake of SC@FNPCN-333 was inhibited by either low 
temperature incubation (4 oC) or amiloride, viability against PQ was barely improved 
compared to cells not pre-treated withSC@FNPCN-333. Together, these results confirm 
that SC@FNPCN-333 protects cells from ROS-induced toxicity by eliminating ROS 
species. Finally, similar PQ-protection results were obtained in the presence of dfTAT, 
indicating that differences in intracellular localization (cytosolic versus endocytic) does 
not significantly impact the ROS detoxifying capacity of the enzyme nanofactories. Given 
that L.E./LYS are extremely degradative and potentially more damaging than the 
cytosolic space, we next tested the long-term performance of the enzymes nanofactories 
in this environment for maximal stringency.  
To maximize their application and usefulness, enzyme nanofactories should have a 
persistent effect inside cells. To test whether SC@FNPCN-333 could sustain its 
protecting effect beyond 24 h, cells pre-incubated with SC@FNPCN-333 were cultured 
with fresh DMEM buffer for up to a week. PQ-induced toxicity was evaluated at day 2 
and day 7. As shown in Figure IV-9, treating cells with free SOD and CAT, which 
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provided only a weak protective effect at day 0, failed to rescue cells from PQ-induced 
cytotoxicity at day 1. In contrast, the rescuing effect of SC@NPCN-333 at day 2 was 
similar to that obtained at day 1. Moreover, this effect, although partially diminished, 
remained significant at day 7. This long-term persistence is consistent with the stability of 
the MOF material detected in vitro, where little protein leaching out of the MOF is 
observed over 7 days in an acidic milieu. Notably, ICP-MS analysis shows that the 
intracellular aluminium content present at day 7 was approximately 6% of that of cells at 
day 0 (1600 ng Al per 105 cells are detected after incubation of 75 g mL-1 of 
SC@FNPCN-333 at day 0, 104 ng Al per 105 cells at day 7). This is therefore indicative 
of a decline in overall MOF concentration of present in cells overtime, as would be 
expected from the dilution that take place during each cell division during one week of 
 
Figure IV-9. Long-term protection of HeLa cells from oxidative stress by SC@FNPCN-333. 
(a) Timeline of the experiment. Cells were pretreated with SC@FNPCN-333 (75 µg mL-1, 2 
h), washed and cultured for several days (grey time period in scheme). Cells were then treated 
with PQ (24h incubation) and cell viability was quantified. (b) Outcome of the experiment. 
Dark blue: control of cells not pretreated with SC@FNPCN-333. Dark magenta: cells pre-
treated with SOD (60 µg mL-1) and CAT (94.5 µg mL-1), PQ-protection assessed 24 h post-
treatment. Green: cells pre-treated with SC@FNPCN-333 (75 µg mL-1), PQ-protection 
assessed 48 h post-treatment. Orange: cells pre-treated with SC@FNPCN-333 (75 µg mL-1), 
PQ-protection assessed 168 h post-treatment. n = 5, mean ± s.d. *** represents P≤0.001. 
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cell culture. However, titration experiments confirmed that lower doses of SC@FNPCN-
333 could maintain high protection activities in cells. In particular, while incubation of 
cells at 1 g mL-1 SC@FNPCN-333 provides no protective effect, incubation with 2.5 g 
mL-1 SC@FNPCN-333 leads to approximately 100 ng Al per 105 cells and 70% cell 
viability after PQ treatment (a condition similar to that obtained at day 7 after incubation 
of 75 g mL-1 SC@FNPCN-333). Overall, these results indicate that the prolonged effect 
of SC@FNPCN-333 is imparted by the chemical stability of the material as well as its 
sustained enzymatic activity even at low intracellular concentrations.  
 
4.4 Summary and Discussion 
 This report establishes that enzymatic nanofactories based on MOF can sustain 
intracellular enzymatic activities for an extended period of time. The proteins 
encapsulated within the MOF structure are enzymatically active, indicating that proper 
enzyme folding is achieved and maintained within the MOF and that soluble substrates 
and products can diffuse in and out of the MOF-enzyme nanofactories. The MOF act as a 
nanocage that protects encapsulated enzymes from proteases and the acidic environment 
inside L.E./LYS. The mechanism of protease-resistance presumably involves restricting 
the access of a protease to its protein substrate, in this case CAT and SOD. In particular, 
while trypsin may be small enough to enter an empty MOF cavity, it is unlikely that it 
would be able to do so if the cavity is already loaded with SOD or CAT. Alternatively, 
the MOF environment may stabilize the folding/structure of encapsulated enzymes. This 
would also contribute to improving protease resistance (unstructured proteins are more 
readily proteolized than folded proteins) and could explain how the MOF prevents pH-
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induced unfolding and loss of activity. Overall, these features provide a material that 
persists in the lumen of L.E./LYS, a highly degradative cellular milieu that combines a 
high density of proteases and acidic pH. Based on our in vitro and in cellulo data, it is 
likely that free enzymes are rapidly degraded in these organelles. It is also likely that it is 
the slow leaching of enzymes from the MOF structure that contribute to the gradual loss 
of activity detected in live cells.  
It is notable that the proximity of SOD and CAT in the enzymatic nanofactory 
enhances the protective effect against PQ induced oxidative stress. SOD catalyzes the 
disproportionation of superoxide and generates H2O2 and oxygen, while H2O2 is 
consumed by CAT, yielding water and oxygen. Since the two reactions catalyzed by SOD 
and CAT may occur in a cascade manner, it is likely that SOD-generated H2O2 is 
degraded by CAT before this ROS diffuses away from the nanofactory. Conversely, in the 
case of MOF nanoparticles carrying only one enzyme, the H2O2 generated by 
S@FNPCN-333 may be more likely to diffuse away from C@FNPCN-333 before 
detoxification can occur. The ROS that escapes the nanofactories may then reach the 
cytosolic area and cause oxidative damage, inducing increased toxicity, as observed.  
In contrast to the proximity effect, altering the localization of SC@FNPCN-333 
(endocytic vs. cytosolic) did not result in significant difference in protecting cells from 
PQ induced oxidative stress. On one hand, this is surprising as one may expect cytosolic 
SC@FNPCN-333 to come into contact with more diffusing ROS than SC@FNPCN-333 
trapped inside endocytic organelles. On the other hand, it is interesting to note that 
endosomes redox active and that they contain proteins capable of mediating the transport 
of ROS across bilayers.255-257 It is therefore possible that a significant portion of PQ-
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generated superoxide reaches the lumen of endocytic organelles. Under such scenario, 
endocytic and cytosolic SC@FNPCN-333 would show similar activities by detoxifying 
cells from the damaging effects of superoxide, before or after in penetrates endosomes, 
respectively. 
 Given the multiple criteria that have to be taken into account to generate optimal 
nanofactories, it is difficult to predict which enzymes may be compatible with MOF 
encapsulation. Several aspects of a MOF-based strategy however point to a potentially 
broad applicability. For instance, the diameter of the MOF cavities is tunable, providing 
opportunities for the encapsulation of enzymes of various sizes. It is also possible to 
encapsulate a cocktail of enzymes, something that can lead to synergistic effects as 
demonstrated by the fact that SC@FNPCN-333 clearly outperforms the combination of 
S@FNPCN-333 and C@FNPCN-333. Additionally, the size and surface of the MOF can 
also be modified. This in turn could facilitate development of nanofactories that reside 
inside cells for even longer periods of time. Moreover, the compatibility of MOF 
nanofactories with dfTAT mediated cytosolic delivery highlights that these materials have 
access to the cytosolic space of live cells. While it did not lead to improvements in the 
context of SC@FNPCN-333, this is presumably important for the future development of 
nanofactories that would involve substrates that are confined within the cytosolic space, 
as is the case for numerous molecules associated with different metabolic pathways. 
 A side by side comparison between the nanofactories presented in this study and 
other reported enzyme protection techniques is difficult.258-260 This is in part because the 
enzymes encapsulated often vary, persistence in cells is often not documented, and 
because each technique has a different set of advantages and disadvantages. Nonetheless, 
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we propose that in vitro performances of the nanofactories achieved in this proof-of-
concept study are extremely encouraging. Moreover, MOFs provide specific benefits over 
other encapsulation materials. For instance, liposomes, the most common enzyme carrier 
system, protect enzymes from degradation effectively. However, the lipid bilayer of 
liposomes forms a barrier between enzyme and substrate. Enzyme protection therefore 
comes at the cost of a severe reduction in enzymatic activity, unless complex strategies 
are implemented to permit substrate diffusion or controlled enzyme release. In contrast, 
MOF-encapsulated enzymes remain accessible to substrate without the need of enzyme 
release from the carrier. As a matter of fact, the activity of encapsulated enzymes is 
comparable to that of the enzymes in their free form. MOF encapsulation, and protection 
from proteolytic degradation, therefore does not compromise enzymatic activity. This is 
turn allows for simple design and nanparticle synthesis (i.e. no need for release 
strategies). 
While the biocompatibility of MOF, in cellulo and in vivo, certainly needs to be 
further tested, these results point to various potential biotechnological approaches. For 
instance, by varying the enzymes encapsulated within the MOF structures, nanofactories 
such as those described herein may replace defective metabolic activities and contribute 
to enzyme replacement therapies. Moreover, we envision that MOF-enzyme nanofactories 
may find applications in cell biology and ex vivo cell engineering. For instance, 
SC@FNPCN-333 may be readily useful for cultures of cells prone to oxidative stress (e.g. 
primary cells). MOF-enzyme nanofactories may also be useful as organelle mimetics that 
confer cells novel properties, including resistance to various stresses.261-265 We also 
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envision that MOF-enzyme nanofactories, if combined with reporter assays, could allow 
the probing of metabolic activities in cell cultures over extended periods of time. 
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CHAPTER V 
LONG-PERSISTENT ENZYME-MOF NANOREACTOR ACTIVATES NON-TOXIC 
PARACETAMOL FOR CANCER THERAPY5 
5.1 Introduction 
Chemotherapeutics typically interfere with mitosis and demonstrate maximum 
toxicity towards rapidly-dividing cells.266 However, chemotherapy drugs are poorly 
selective and often result in severe adverse effects that include kidney damage, bone 
marrow suppression, nerve damage, hair loss, low blood count, and inflammation.267-269 
In addition, resistance to chemotherapy occurs in certain cancer cell lines, thereby 
declining the efficiency of treatment.270-272 One strategy to approach these problems is to 
employ prodrugs, compounds that are innocuous until metabolized to give cytotoxic 
products in a tumor microenvironment.273-276 However, this approach involves a new 
challenge, the identification of activation mechanisms specific to cancer cells. To date, 
enzymes overexpressed in tumor cells have been used to activate prodrug.275, 277 
Nevertheless, because these targeting enzymes may also present in normal cells, albeit at 
lower levels, many of these prodrug therapies retained poor selectivity and demonstrated 
minimal success. 278, 279 To circumvent this, an alternative strategy involves delivering 
exogenous “activating” enzymes into cancer cells. Tumor specific accumulation of the 
enzyme “activator” is achieved by conjugation to tumor directing antibodies or 
immunoliposomes.280-283 While potentially useful, the biggest drawback is that externally-
administered enzymes are highly vulnerable to degradation in the bloodstream.284, 285 
5Reproduced with permission from “Long-Persistent Enzyme-MOF Nanoreactor Activates Non-toxic 
Paracetamol for Cancer Therapy” by Lian, X.; Huang, Y.; Zhu, Y.; Fang, Y.; Zhao, R.; Joseph, E.; Li, J.; Pellois, J.-P.; 
Zhou, H.-C. Angew. Chem. Int. Ed., 2018, 57, 5725-5730, copyright 2018 by John & Wiley Sons. 
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Thus the feasibility of this strategy remains unclear and strategies that can improve the 
biocompatibility of externally-administered enzymes are needed. 
Herein we demonstrate that enzymatic nanoreactors based on metal-organic 
frameworks (MOFs) can be potent prodrug activators. MOFs are an emerging platform 
that demonstrates potential for a number of biotechnological applications, including 
sensing, imaging, drug delivery and enzyme encapsulation.129, 141, 220, 286-297 Encapsulated 
enzymes demonstrate well-preserved catalytic activities.129 Encapsulated enzymes also 
show enhanced stability under protein denaturation conditions, such as organic solvents, 
extreme pH environments, or high temperatures.138, 139, 298 Moreover, MOFs efficiently 
protect encapsulated enzymes from proteolytic degradation, presumably by preventing 
access of proteases to the protein substrate.141, 299 Notably, the porous nature of MOFs 
allows for facile substrate diffusion and product release, a feature typically superior to 
 
 
Scheme V-1. Nontoxic prodrug APAP oxidation is catalyzed by tyrosinase, yielding cytotoxic 
AOBQ, which induces ROS generation and GSH depletion. 
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other well-established carriers.300 In this work, we selected PCN-333(Al) as the enzyme 
carrier owing to its high enzyme encapsulation capacity, facile modification with 
fluorophores, and chemical robustness in cellular environment.289 To achieve tumor 
specific prodrug activation, tyrosinase (TYR), which is uniquely localized in melanocytes 
and melanoma cells, is chosen as the activating enzyme.301 Paracetamol (APAP), the 
active ingredient of Tylenol, is used as the nontoxic prodrug.302 Both in cellulo and in 
vivo experiments establish that APAP along with enzyme-MOF nanoreactor induced 
significant cytotoxicity in drug-resistant cancer cells and led to tumor regression. 
Mechanistically, cytotoxicity arises from 4-acetamido-o-benzoquinone (AOBQ), the 
enzymatic conversion product of APAP, and from subsequent reactive oxygen species 
(ROS) generation and glutathione (GSH) depletion. 
 
5.2 Experimental Section 
5.2.1 Material and Instrumentation 
Aluminum chloride hexahydrate, N-bromosuccinimide (NBS), benzoyl peroxide 
(BPO), ethylenediamine, triethylamine, trifluoroborane etherate, N-hydroxysuccinimide, 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide (EDC), N,N-dimethylformamide 
(DMF), tetrahydrofuran (THF), potassium carbonate, hydrochloric acid and sodium 
hydroxide were purchased from VWR. Carbon tetrachloride, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) and tyrosinase (TYR) were purchased from 
Sigma Aldrich. Dulbecco’s minimum essential medium (DMEM), Roswell Park 
Memorial Institute (RPMI) 1640 Medium, 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES), Leibovitz's L-15 medium without cysteine (non-
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reducing L-15, nrL-15), 10% fetal bovine serum (FBS) and 1× penicillin/streptomycin 
(P/S), Lyso Tracker red, Annexin V-FITC/Propidium Iodide (PI) apoptosis assay kit and 
real-time superoxide fluorescent assay kit were purchased from Thermo Fisher Scientific. 
Superoxide detecting reagent was purchased from Enzo life science. Glutathione (GSH) 
colorimetric assay kit was purchased from BioVision.  
Synthetic manipulations that required an inert atmosphere (where noted) were 
carried out under nitrogen using standard Schlenk techniques. Powder X-ray diffraction 
(PXRD) was carried out on a Bruker D8-Focus Bragg-Brentano X-ray powder 
Diffractometer equipped with a Cu sealed tube (λ = 1.54178) at 40 kV and 40 mA. N2 
sorption isotherms at 77 K were measured by using a Micrometritics ASAP 2420 system 
with high-purity grade (99.999%) of gases. UV-Vis spectra were recorded on Shimadzu 
UV-2450 spectrophotometer. Fluorescence spectra were recorded on a Hitachi F- 4600 
spectrometer (Hitachi Co. Ltd., Japan) with Xe lamp as the excitation source at room 
temperature. Dynamic light scattering and Zeta potential were measured at 25 °C on a 
Zetasizer Nano ZS ZEN3600 analyser (Malvern Instrument Ltd, UK). Confocal laser 
scanning microscopy (CLSM) imaging was performed on an inverted epifluorescence 
microscope (Model IX81, Olympus) was equipped with a heating stage maintained at 37 
°C. Images were collected using a Rolera-MGI Plus back-illuminated electron-
multiplying charge coupled device (EMCCD) camera (Qimaging). Images were acquired 
using bright-field imaging and three standard fluorescence filter sets: DAPI (excitation 
(Ex) = 350 ± 10 nm/emission (Em) = 440 ± 20 nm), RFP (Ex = 560 ± 20 nm/Em = 630 ± 35 
nm) and FITC (Ex = 488 ± 10 nm/Em = 520 ± 20 nm). The fluorescence intensities of 
different cells were measured with the SlideBook 4.2 software (Olympus). For 
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fluorescence measurement using the flow cytometer, cells were trypsinized and 
resuspended in nrL-15 medium. Cells were analyzed using a BD Accuri C6 flow 
cytometer equipped with the FL2 filter (excitation = 488 nm/emission = 533 ± 30 nm). 
All data were acquired at a flow rate of 66 µl/min with detection of a minimum of 40,000 
events. The data was processed using Flowjo software. 
HeLa (ATCC CCL-2) were grown in DMEM supplemented with FBS and P/S and 
kept at 37 °C in a humidified atmosphere containing 5% CO2. SKOV3-TR (ATCC HTB-
77) and H1299 (ATCC CRL-5803) were grown in RMPI 1640 supplemented with FBS 
and P/S and kept at 37 °C in a humidified atmosphere containing 5% CO2. Cell 
experiments are performed in quintuplicates for each condition, and are repeated with 
three different batches of cells. Statistic tests are studied by multiple t tests method. 
Female BALB/c nude mice (5–6 weeks) were purchased from Vital River 
Laboratories (Beijing, China). All animal experiments were performed in accordance with 
the Guide for the Care and Use of Laboratory Animals, and were approved by the 
Experimental Animal Ethics Committee in Beijing. Mice were subcutaneously injected 
with HeLa cells (3107 /mL, 200 L) at the flank. After the tumor volume reached ~50 
mm3, the mice were randomly divided to 5 groups, with five mice in each group. The 
tumor-bearing mice in the 5 groups were treated with PBS, APAP, TYR@NPCN-333, 
TYR@NPCN-333 – APAP, and TYR@NPCN-333 – APAP + GSH, respectively every 
day via intratumor injection (100 L). Tumor volume were measured every day and 
calculated by Tumor volume = (length  width2)/2. On day 7, mice were euthanized. The 
tumor tissues of each mice were collected and finally fixed in formalin. Hematoxylin and 
eosin (H&E) staining of the tissues was performed according to standard protocol. 
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5.2.2 Synthesis of NPCN-333 
10 mL DMF solution of AlCl3· 6H2O (1.5 mg/mL), 5 mL DMF solution of TATB 
(1 mg/mL), 15 mL DMF and 50 μL TFA was mixed and heated at 95oC for 24 h. NPCN-
333 was collected by centrifugation. 
5.2.3 Synthesis of FNPCN-333 
30 mg NPCN-333 was dispersed in 5 mL DMF in which was added 5 mL 10 
mg/mL DMF solution of BTB-Green. The mixture was kept in 85oC oven for 4 h and the 
solid was collected by centrifugation. The precipitated solid was washed with fresh DMF 
for 3 times and resuspended in fresh DMF. 
5.2.4 Encapsulation of TYR on NPCN-333 
Stock solutions of TYR (3 mg/mL) was prepared by dissolving TYR in deionized 
water. 1 mg NPCN-333 was suspended in water in which 1 mL TYR stock solution was 
added. The mixture was vortexed for 20 minutes and the solid was collected by 
centrifugation and washed by fresh water for 3 times.  
5.2.5 Theoretical estimation of enzyme loading in NPCN-333 
In each unit cell of PCN-333, there are eight of A-cages (5.5 nm) and 16 of B-
cages (4.2 nm). The volume of each unit cell = (126 Å)3 = 2.0 × 10-18 cm3. The density of 
PCN-333(Al) = 0.23 g/cm3. So the mass of each unit cell = ρ × V = 0.46 × 10-18 g. 
Therefore, the total number of unit cells per gram of PCN-333(Al) is: 1/(0.46 х 10-18) = 
2.2 х 1018. And the A-cage in each gram of PCN-333(Al) = 2.2 × 1018 × 8 = 1.7 × 1019 = 
2.9 × 10-5 mol. For TYR, MW = 43 kDa, so the maximum loading is 43000 × 2.9 × 10-5 = 
1.075 g/g. 
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5.2.6 Enzymatic activity study 
In 50 mM pH 6.8 Tris-HCl buffer at ambient temperature containing various 
concentrations of APAP (0.2 – 2mM), free TYR or TYR@NPCN-333 was added and a 
final concentration of 60 µg/mL TYR was obtained. The readings at 450 nm were 
collected every two minutes and were plotted to determine the conversion rate at each 
substrate concentration. Then the results were fit by Michaelis-Menten model and kcat was 
calculated by vmax/[E0]. E0 stands for the concentration of enzyme. 
5.2.7 Long-term persistence of enzymatic activity of TYR@NPCN-333 
Free TYR and TYR@NPCN-333 was incubated with SKOV3-TR for 6 h on day 0, 
respectively. The cells were then cultured with fresh RPMI 1640 medium for several 
days. The culture medium was replaced with medium containing APAP on day 1 (free 
TYR) or on day 3 (TYR@NPCN-333) and cultured for 24 h. Cell viability was measured 
by MTT assay. 
5.2.8 Cell internalization of TYR@FNPCN-333 and CLSM imaging 
SKOV3-TR cells were seeded in an 8 well plate and allowed to grow for 24-48 h. 
Then the culture media was replaced by 200 µL fresh nrL-15 media containing 75 µg/mL 
TYR@FNPCN-333 at 37oC for 6 h in darkness. Culture media was removed and the cells 
were washed with fresh nrL-15 media for 3 times. Lyso Tracker red was added before the 
cells were subjected to microscope.  
5.2.9 MTT assay for viability determination 
Cells were seeded in 96 well plate and subjected to certain treatments. Then 
culture media was removed and the cells were washed with fresh PBS buffer for 3 times. 
100 µL fresh RPMI 1640 buffer was added to each well followed by the addition of MTT 
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stock solution. The final MTT concentration is 0.5 mg/mL. The plate was incubated at 
37oC for 4 h. 100 µL SDS-HCl (10 mM) stock solution was added to each well and the 
plate was incubated at 37oC for another 12 h. The solution in each well was mixed and the 
absorbance at 560 nm was collected on a plate reader. 
5.2.10 Annexin V-FITC/PI assay for determining the apoptotic status of cells by flow 
cytometry 
Cells were seeded in 48 well plate and subjected to certain treatments. Then the 
cells were trypsinized and washed with cold PBS buffer for three times collected by 
centrifugation. Cells were treated with 5% annexin V-FITC and 100 µg/mL PI in binding 
buffer for 15 minutes at room temperature before subjected to flow cytometry for 
analysis.  
5.2.11 Intracellular ROS monitoring 
Cells were seeded in 48 well plate and subjected to certain treatments. Then the 
culture media was removed and the cells were cultured in fresh RPMI 1640 media 
containing 20 µM superoxide detecting reagent for 15 minutes. The cells were then 
imaged using a confocal microscope. 
5.2.12 Intracellular GSH concentration measurement 
This measurement is followed by the protocol from BioVision. Cells were seeded 
in 6-well plate (1-1.5 × 106 cells per well) and were allowed to adhere overnight. The 
cells were treated by desired methods. Collect the cells by centrifugation at 700 × g for 5 
minutes at 4oC. Remove the supernatant. Wash the cells with ice cold PBS. Lyse the cells 
in 80 µL ice cold glutathione buffer. Incubated on ice for 10 minutes. Add 20 µL 5% 
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sulfosalicylic acid (SSA) solution, centrifuge and remove the pellet. Use the supernatant 
for glutathione assay. 
Prepare NADPH generation solution by mixing 20 µL NADPH generating mix, 20 
µL glutathione reductase and 120 µL glutathione reaction buffer in a 96-well plate and 
wait for 10 minutes at room temperature. Add 20 µL GSH standard solution or sample 
solution and incubate the plate for 5-10 minutes. Add 20 µL of DNTB solution and 
incubate for another 5-10 minutes. Read the absorbance at 405 nm using a microplate 
reader. Determine concentrations of GSH in the sample solutions using the standard 
curve. 
 
5.3 Results and Discussion 
PCN-333 is composed of trimeric-oxo cluster and a planar triangular ligand, 
4,4′,4″-s-triazine-2,4,6-triyl-tribenzoic acid (TATB), which self-assembles into a 
supertetrahedron (STH) with metal clusters on the corner and TATB on the face (Figure 
V-1). A 1.5 nm cavity is present in the STH. Two types of mesoporous cavities with 
diameters of 4.2 and 5.5 nm are composed of STHs through vertex sharing. PCN-333 
 
Figure V-1. Structure of PCN-333. (a) NPCN-333 is composed of aluminum trimeric cluster 
and TATB ligand, which self-assembles into supertetrahedrons as the secondary building 
block of NPCN-333. (b) Two types of mesoporous cavities in NPCN-333: 4.2 nm 
dodecahedral cage (light purple) and 5.5 nm hexacaidecahedral cage (light green). Based on 
the size of tyrosinase, it can only be accommodated in the 5.5 nm cage. 
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nanoparticles (NPCN-333) were prepared by solvothermal reaction of AlCl3 and TATB in 
DMF at 95oC. The particle size determined by transmission electron microscopy (TEM) 
was around 100 nm (Figure V-2). A fluorescent version of NPCN-333 was prepared via a 
ligand metathesis reaction with a BTB ligand functionalized with a green fluorescent 
BODIPY fluorophore. The well-maintained crystallinity of NPCN-333 after enzyme 
loading and after soaking in cell culture medium Roswell Park Memorial Institute 1640 
 
Figure V-2. Structural characterization of NPCN-333. TEM images of NPCN-333 (a), 
TYR@NPCN-333 (b), and TYR@NPCN-333 after soaking in RPMI-1640 for 7 days (c). 
Scale bar: 200 nm. (d) Powder X-ray diffraction (PXRD) patterns of pristine NPCN-333 
(black), TYR@NPCN-333 (red), TYR@NPCN-333 after trypsin treatment (blue), and 
TYR@NPCN-333 after soaking in RPMI 1640 media for 7 days (magenta). (e) Particle size 
distribution measured by dynamic light scattering (DLS): (from front to back) pristine 
NPCN-333, TYR@NPCN-333, TYR@NPCN-333 after trypsin treatment, and 
TYR@NPCN-333 after soaking in RPMI 1640 media for 7 days. 
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(RPMI 1640) for up to 7 days was confirmed by the TEM images and by the nearly 
unchanged PXRD pattern (Figure V-2). The monodispersity of NPCN-333 immersed in 
RPMI 1640 over an extended period of time was verified by the particle size distribution 
diagram derived from dynamic light scattering (DLS) data collected on day 0 and day 7 
(Figure V-2). 
One molecule of TYR contains a single 43 kDa polypeptide with dimension of 5.5 
× 5.5 × 5.6 nm3.303 Therefore TYR may be accommodated in the 5.5 nm cavity, but 
presumably not in the 1.5 and 4.2 nm cavity. After incubating TYR with NPCN-333 
slurry for 20 minutes, the enzyme loading capacity was estimated to be 0.80 g/g 
according to BCA method, which is in consistent with the theoretical value (1.08 g/g). 
The distribution of TYR in the material was studied by N2 isotherm at 77K. The pore size 
distribution diagram of TYR encapsulated NPCN-333 (TYR@NPCN-333) clearly 
showed the presence of a microporous cavity around 1.5 nm and a mesoporous cavity at 
around 4 nm. Notably, the 5 nm cavity disappeared, consistent with the cavity being 
occupied by TYR. Thermal gravimetric analysis (TGA) also indicated the high loading of 
TYR in NPCN-333. 
TYR catalyzes the oxidation of APAP to an o-quinone compound, 4-acetamido-o-
benzoquinone (AOBQ), which absorbs at 450 nm. The enzymatic activities of free TYR 
and TYR@NPCN-333 nanoreactor in 50 mM Tris-HCl buffer (pH 6.8) at ambient 
temperature, was monitored by UV-vis spectrometry. TYR@NPCN-333 nanoreactor 
followed Michaelis-Menten kinetics and showed a kcat value of 0.377 s-1 and a Km value 
of 1.119 mM. In comparison, the free enzyme displayed a kcat of 0.405 s-1 and a Km of 
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1.338 mM. The catalytic efficiencies, kcat/Km, were 0.302 s-1mM-1 for free TYR vs. 0.337 
s-1mM-1 for TYR@NPCN-333. 
Resistance of enzyme-MOF nanoreactor towards degradation is critical for 
practical applications in living biosystems. To elucidate whether NPCN-333 could protect 
encapsulated TYR, free TYR and TYR@NPCN-333 were incubated with trypsin solution 
for 2 hours at 37oC. Then, the enzyme was released by dissolving TYR@NPCN-333 with 
HCl and the supernatant was subjected to SDS-PAGE analysis. Free TYR was readily 
digested by trypsin as illustrated by the presence of small molecular weight bands. In 
contrast, bands corresponding to intact TYR were predominantly present for 
TYR@NPCN-333. Additionally, the enzymatic activity of TYR@NPCN-333 was almost 
unchanged after trypsin treatment (Figure V-3). Moreover, in order to study whether 
MOF protect encapsulated enzymes in an acidic medium, free TYR and TYR@NPCN-
333 were incubated in pH 5 buffer, and enzymatic activities were measured at 2 h and 12 
h. While a 2 h incubation only resulted in a 15% activity loss on free enzyme, 75% of the 
 
Figure V-3. Long-persistent enzymatic activity of TYR@NPCN-333 under perturbations. (a) 
AOBQ generation catalyzed by TYR@NPCN-333 before (red) and after (green) trypsin 
digestion. (b) Relative enzymatic activities (compared with activities in pH 5 at 0 h) of 
TYR@NPCN-333 and free TYR after incubating in pH 5 solution for 2 h and 12 h. 
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original activity was lost after 12 h incubation. In contrast, TYR@NPCN-333 maintained 
over 75% activity after 12 h incubation at pH 5 (Figure V-3). 
In vitro results indicated that TYR@NPCN-333 is enzymatically active and 
relatively resistant to perturbations. Cell-based experiments were therefore conducted to 
examine whether TYR@NPCN-333 could activate APAP in cancer cells. To test the 
performance of TYR@NPCN-333, we chose SKOV3-TR, an ovarian adenocarcinoma 
cell that is resistant to cisplatin, tumor necrosis factor, diphtheria toxin, adriamycin, and 
taxane.304-306 First, the cellular internalization of the enzyme-MOF nanoreactor was 
established using confocal microscopy. A fluorescent particle, TYR@FNPCN-333, was 
used to monitor cellular trafficking. After incubation with cells, TYR@FNPCN-333 
 
 
Figure V-4. Cytotoxicity of TYR@NPCN-333 – APAP. (a) Cell proliferation of SKOV3-TR 
cells upon different treatments measured by MTT assay. The experiment was performed in 
quintuplicate in 96 well plates (n = 5), mean ± s.d., *** represents p≤0.001, multiple t test. (b) 
Cell viability of SKOV3-TR cells stained with annexin V-FITC/propidium iodide (PI) and 
measured by flow cytometry after different treatments. Cells with (+) or without (-) 6 h 
TYR@NPCN-333 pretreatment was incubated with 0—2 mM APAP for 2 h. The experiment 
was performed three times and representative results from one test are displayed. 
 
 
110 
 
displayed an intracellular punctate distribution around the nucleic area that colocalizes 
with LysoTracker, a marker for late endosomes and lysosomes.307 This indicates that the 
nanoreactor accumulated within endocytic organelles. Next, the cytotoxicity induced by 
TYR@NPCN-333 was quantified by the MTT assay. The prodrug, or the enzyme-MOF 
nanoreactor, did not display any noticeable cytotoxicity (Figure V-4). In contrast, cells 
that were pretreated with TYR@NPCN-333 for 6 h, and then subsequently exposed to 
increasing concentrations of APAP (0.1 to 2 mM) displayed a correlated decrease in 
viability. In complementary assays, the cytotoxicity of the TYR@NPCN-333 – APAP 
combination was assessed by flow cytometry. After different treatments, cells were 
stained with annexin V-FITC, a fluorescent marker of surface exposed phosphatidyl 
serine, and with propidium iodide (PI), a DNA stain that detects the permeabilization of 
the plasma membrane. As observed previously, neither APAP nor TYR@NPCN-333 
 
 
Figure V-5. Long-term persistence of enzymatic activity of TYR@NPCN-333. The 
experiment was performed in quintuplicate in 96 well plates (n = 5), mean ± s.d., *** represents 
p≤0.001, multiple t test. 
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caused an increase in annexin V or PI staining, indicating that these conditions are not 
toxic to cells (Figure V-4). However, cells pretreated with TYR@NPCN-333 and exposed 
to APAP displayed dual labeling, which is indicative of cell death. 
Because activating enzymes must be administered before treatment with a prodrug, 
it is important to ensure that their activity can be maintained over a prolonged period of 
time.308 To study how the enzyme-MOF nanoreactor performs in this respect, SKOV3-TR 
cells pretreated with TYR@NPCN-333 for 6 h were cultured in fresh media for several 
days. MTT assay revealed that a 2 mM APAP treatment on day 3 could lead to 50% cell 
proliferation inhibition (Figure V-5). On the contrary, free TYR showed slight inhibition 
effect (<20%) on cells after APAP treatment on day 0. However, the activity of free TYR 
totally disappeared from day 1. Besides, similar cytotoxicity was observed in other cancer 
cell lines, including non-small lung carcinoma cell H1299 and cervical carcinoma cell 
HeLa. 
Next, we sought to characterize how TYR@NPCN-333 – APAP induces toxicity. 
When used as the sole therapeutic, neither TYR@NPCN-333 nor APAP display 
cytotoxicity. We hypothesized that the cytotoxicity observed was a result of the in situ 
generation of AOBQ as an enzymatic product. Based on the property of p-quinone 
compounds, we suspected that AOBQ would undergo single electron redox reactions and 
induce the generation of reactive oxygen species (ROS) in cells.309-312 Real-time 
monitoring of superoxide (O 
 ) concentration using a superoxide detection reagent in 
SKOV3-TR cells upon different treatments was performed to test this hypothesis. The 
intensity of red fluorescence is proportional to the concentration of intracellular O 
 . Cells 
treated with TYR@NPCN-333 – APAP displayed elevated levels of O 
  whereas the O 
  
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level in cells treated with either TYR@NPCN-333 or APAP remained unchanged (Figure 
V-6). 
Besides inducing ROS generation, o-quinone compounds are notorious for 
consuming glutathione (GSH) in living cells.313, 314 Therefore we sought to measure the 
GSH concentration in cells upon TYR@NPCN-333 – APAP treatments. GSH reacts with 
DNTB (5,5’-dithio-bis-2-(nitrobenzoic acid) and produces a yellow colored compound 
(5-thio-2-nitrobenzoic acid), which can be quantitatively measured by UV-vis 
spectroscopy at 405 nm.315 Because GSH is the most abundant non-protein thiol in 
eukaryotic cells, this measurement yields a good estimation on intracellular GSH 
concentration.316 GSH level remained unchanged in cells treated with either 
TYR@NPCN-333 or APAP. However, when cells were pretreated with TYR@NPCN-
333 for 6 h, treatment with APAP solution resulted in GSH depletion, which showed a 
strong correlation with APAP concentration (Figure V-7). Notably, after 2 mM APAP 
 
 
Figure V-6. Real-time monitoring of intracellular superoxide generation. (a) 2 mM APAP 2 
h. (b)-(f) Cells were pretreated with TYR@NPCN-333 for 6 h, then incubated with (b) 0 mM, 
(c) 0.1 mM, (d) 0.5 mM, (e) 1 mM, (f) 2 mM APAP for 2 h. The concentration of superoxide 
is proportional to the intensity of red fluorescence. The experiment was performed three 
times and representative results from one test are displayed. Scale bar: 50 µm. 
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treatment for only 2 h, intracellular GSH concentration decreased to about 50% of its 
original level (cells were not permeabilized at this time point, as proved by absence of PI 
staining). Mass spectrometry analysis of the cell lysate revealed the presence of a species 
with molecular weight of 492, which is in consistent with that of APAP-GSH conjugate 
(Figure V-7).313 In addition, to further confirm the role of ROS generation and GSH 
depletion in AOBQ induced cytotoxicity, we did two control experiments in which 
ascorbic acid (AA) and GSH were supplemented to cell culture medium along with 
TYR@NPCN-333 – APAP treatment (APAP concentration was 500 µM). Compared with 
the negative control group, the cell viability showed 20% and 30% increase for AA and 
GSH supplement groups, respectively. Overall, these results have established that 
TYR@NPCN-333 – APAP exhibits cytotoxicity by inducing oxidative stress, as 
manifested by a combination of ROS induction and GSH depletion. 
 
 
Figure V-7. GSH depletion in SKOV3-TR cells. (a) Intracellular GSH depletion upon various 
treatments for 2 h determined by DNTB assay. The experiment was performed in quintuplicate 
in 96-well plates (n = 5), mean ± s.d., ** represents p ≤0.01, *** represents p≤0.001, multiple 
t test. (b) Mass spectrometry of APAP-GSH adduct. The inlet molecular structure is the 
proposed APAP-GSH adduct. 
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To evaluate the antitumor efficacy of APAP in the presence of MOF nanoreactor, 
in vivo experiments were performed on a HeLa subcutaneous xenograft model. Mice were 
 
 
Figure V-8. In vivo antitumor efficiency of TYR@NPCN-333 – APAP. (a) Time-dependent 
relative tumor growth upon different treatments. The experiment was performed on five 
bilateral tumour-bearing mice (n = 5), mean ± s.d., *** represents p≤0.001, multiple t test. (b)-
(f) Tumor images at day 7 upon different treatments: (b) PBS, (c) APAP, (d) TYR@NPCN-
333, (e) APAP + TYR@NPCN-333, (f) APAP + TYR@NPCN-333 + GSH. The experiment 
was performed on five bilateral tumour-bearing mice (n = 5) and representative results from 
one test are displayed. (g) Body weights during 7 days upon different treatments. (h) 
Representative H&E-stained sections of different organs collected at day 7 upon different 
treatments. Scale bar: 50 µm. 
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treated with PBS, TYR@NPCN-333 (1.5 mg/kg), APAP (200 mg/kg), TYR@NPCN-333 
(1.5 mg/kg) and APAP (200 mg/kg), respectively. Compared with PBS control, tumor 
regression only occurred in the group receiving TYR@NPCN-333 – APAP treatment 
(tumor size decreased from ~50 to ~20 mm3), while neither the nanoreactor nor the 
prodrug alone induced any antitumor efficacy (Figure V-8). More importantly, in the 
TYR@NPCN-333 – APAP group, two out of five tumors were completely eradicated by 
the end of the experiment upon a single treatment. Additionally, tumor regression failed 
in mice treated with TYR@NPCN-333 – APAP but supplemented with GSH (700 
mg/kg), further confirming that tumor regression is attributable to oxidative stress. 
Hematoxylin and eosin (H&E) staining of tumor tissues showed that only the group 
receiving TYR@NPCN-333 – APAP therapy demonstrated cell apoptosis/necrosis 
(Figure V-8). 
5.4 Conclusion 
In summary, we demonstrate that the enzyme-MOF nanoreactor can be a highly 
efficient activator for resistant cancer therapy coupled with a prodrug. Encapsulated 
enzymes are well protected by MOFs in proteolytic conditions and in acidic environment, 
where free enzymes would quickly lose activity. The prodrug can be efficiently activated 
by the enzyme-MOF nanoreactor, generating a cytotoxic compound, which inhibits cell 
proliferation and induces apoptosis/necrosis by promoting oxidative stress. In vivo 
experiment shows a 2.5-time regression of tumor volume after a single treatment. Overall, 
we envision that the enzyme-MOF nanoreactor system as a new platform for vast 
biomedical and biotechnological applications due to the ability to cater for intrinsic 
diversities in structure and functionality. 
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CHAPTER VI 
CONCLUSION 
The majority of this dissertation described the development of novel enzyme-MOF 
nanoreactors and their applications in cell biology and biomedical aspects. Based on a 
hierarchical mesoporous structure, namely PCN-333, isoreticular chemistry resulted in the 
successful preparation of a novel hierarchical mesoporous MOF, PCN-888, possessing 
extremely large cage cavitiess. Because of its hierarchical porosity, two enzymes with 
different sizes could be coupled as a tandem nanoreactor based on size selectivity. The 
relatively small window opening of the cage cavity prevented enzyme leaching and 
protected encapsulated enzymes from trypsin digestion. 
Owing to the better chemical stability of PCN-333 than PCN-888, a fluorescent bi-
enzymatic nanofactory was obtained based on PCN-333 nanoparticles. Fluorescent ligand 
was anchored on the framework backbone via ligand metathesis. This nanofactory 
contained two antioxidant enzymes: superoxide dismutase (SOD) and catalase (CAT). 
Encapsulated enzymes remained active in conditions mimicking that of lysosomes, 
intracellular organelles that are highly degradable and with low pH values. The 
nanofactory could be endocytosed by different types of cells (human cancer, human 
primary, mice primary), accumulated in lysosomes and could protect cells from oxidative 
damage for as long as seven days.  
The above proof-of-concept work provided opportunity for long-persistent 
biomedical applications of enzyme-MOF nanoreactors. Inspired by the superior enzyme 
protection capability of PCN-333, tyrosinase enzyme was encapsulated on PCN-333 
nanoparticles and a cancer therapeutic nanoreactor was generated. When endocytosed by 
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cancer cells, encapsulated tyrosinase was able to catalyse the oxidation of nontoxic 
prodrug paracetamol, the active ingredient of Tylenol®, generating cytotoxic o-quinone 
compound, which demonstrated anticancer efficacy in several cancer cells, including a 
multi-drug resistant cancer cell line (SKOV3-TR). Mechanistically, o-quinone induced 
superoxide generation and antioxidant depletion in cancer cells. The anticancer efficacy 
of this prodrug activation strategy was confirmed on mice model bearing human tumor 
xenograft. Although the current version of enzyme-MOF nanoreactor did not show tumor 
specific accumulation, surface modifications with tumor directing peptide will potentially 
generate tumor targeting nanoreactors, which may significantly reduce the side effect of 
the cytotoxins. 
Although nanoreactors based on PCN-333 demonstrated long-term chemical 
stability in aqueous solutions, it is still desirable to develop more robust MOFs with even 
longer persistence in physiological conditions or with stability to sustain oral 
administration. However, the stability of many MOFs decreases along with the increase 
of surface area, although these MOFs are composed of high valent metal species. To 
address this issue, synthesizing MOFs with Cr(III) species may gain extra stability 
because of the kinetic inertness of Cr(III). On the other hand, inert Cr(III) species hinders 
both the direct synthesis of Cr(III)-MOFs and direct metal metathesis of trivalent MOF 
templates and Cr(III) ions. Herein a reductive labilization strategy for the facile synthesis 
of mesoporous Cr(III)-MOF was discovered. Using Fe(III)-MOF as the template and 
Cr(II) ions as the metal source, Cr(II) could reduce Fe(III) on the framework backbone, 
generating Fe(II) species which is much more labile than its trivalent counterpart. Then 
Cr(II) could replace Fe(II) on the framework and was oxidized to Cr(III) immediately 
118 
 
when it was exposed to air. Cr(III)-MOF demonstrated much wider pH tolerance (0~11) 
than the Fe(III)-MOF template (3~9) and could accommodate polyethylenimine for 
carbon capture. 
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